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RESUMO 
 
 
 
O envolvimento dos componentes da maquinaria de tradução no desenvolvimento de várias 
neoplasisas é hoje amplamente reconhecido, principalmente no que diz respeito a factores de 
iniciação e factores de alongamento da tradução. Neste contexto, os factores de tradução têm 
sido também encarados como potenciais alvos para a inibição da proliferação celular e 
consequentemente como alvos de terapia contra o cancro. O factor de terminação da tradução 
eucariótico 3 (eRF3) é uma pequena GTPase que se associa com o factor de terminação da 
tradução eucariótico 1 (eRF1) e com o GTP para formar o complexo de terminação da tradução. 
A proteína eRF3 humana existe em duas isoformas, designadas por eRF3a e eRF3b, codificadas 
respectivamente pelos genes eRF3a/GSPT1 e eRF3b/GSPT2. Para além das funções que lhe são 
atribuídas no processo de tradução (terminação da tradução, reciclagem de ribossomas e 
iniciador da degradação do mRNA), este factor está também envolvido no controlo do ciclo 
celular, na organização do citoesqueleto e na regulação da apoptose. As proteínas eRF3a e 
eRF3b apresentam 87% de homologia, sendo a maior diferença entre ambas no seu domínio N-
terminal. A extremidade amina do eRF3a apresenta uma expansão de poliglicinas codificada por 
uma expansão estável do tripleto GGC no exão 1 do gene eRF3a/GSPT1. Este polimorfismo está 
ausente no gene eRF3b/GSPT2. Vários genes contendo expansões de microssatélites exónicos 
têm sido associados ao desenvolvimento de cancro, sendo em alguns casos os polimorfismos 
STR (Short Tandem Repeat) relacionados com a transactivação da expressão dos genes 
respectivos. 
O principal objectivo deste trabalho foi avaliar o gene eRF3a/GSPT1 como potencial gene de 
susceptibilidade para o desenvolvimento de cancro. 
Pela análise do polimorfismo STR no gene eRF3a/GSPT1, foram detectados cinco alelos 
diferentes na população portuguesa contendo 7, 9, 10, 11 e 12 repetições GGC, sendo o alelo 
10GGC o mais comum (F=68.5% na população controlo saudável). O alelo mais longo (12GGC) 
foi detectado exclusivamente em 5.1% dos pacientes com cancro (N=411), com uma frequência 
alélica de 3%, correspondendo a um risco 12 vezes aumentado de desenvolvimento de cancro 
(OR= 11.8; SE=1.43; C.I.=0.71-195.46). Demonstrou-se que não se trata de uma mutação 
somática, mas sim da linha germinal, e que o alelo 12GGC está ausente na população controlo e 
em indivíduos com Doença de Crohn, uma doença inflamatória com elevada predisposição para o 
desenvolvimento de cancro colorectal.  
Recorrendo ao RT-PCR em Tempo Real, verificou-se que o gene eRF3a/GSPT1 se encontra sobre-
expresso em vários tipos de cancro, nomeadamente em 70% dos tumores gástricos do tipo 
intestinal e em 44% dos tumores da mama. Mais ainda, demonstrou-se que existe uma variação 
significativa dos níveis de mRNA em função do tamanho dos alelos expressos, encontrando-se o 
alelo 12GGC sobre-expresso quer em linhas primárias de linfócitos (p<0.001) quer em células 
Jurkat transformadas (p<0.0001), quando comparado com o alelo 10GGC, tomado como 
referência. Os elevados níveis de expressão do gene eRF3a/GSPT1 detectados em tecidos 
RESUMO 
xvi 
tumorais não estão relacionados com um aumento da taxa de tradução das células cancerígenas, 
visto que este aumento não se verifica no principal factor de terminação da tradução (eRF1). 
Também não foram detectadas alterações nos níveis de eRF3b/GSPT2 correlacionadas com as 
variações de expressão do eRF3a/GSPT1, pelo que as alterações de expressão não serão 
ajustadas por um mecanismo de compensação entre as duas isoformas da proteína. A dosagem 
génica do eRF3a/GSPT1 foi também foi determinada através de PCR em Tempo Real mas não 
foram detectadas amplificações/delecções do gene em tecidos tumorais associadas às alterações 
nos padrões de expressão. Os níveis de metilação dos locais CpG localizados na expansão GGC 
foram quantificados por pirosequenciação, mas a variação de 7 a 12 repetições GGC não se 
encontra associada a alterações nos níveis de metilação, independentemente do tipo de tecido 
analisado. Assim, o mecanismo responsável pela sobre-expressão do gene continua por 
esclarecer. 
Estando envolvido em processos críticos e vitais para a célula, é de prever que alterações no 
domínio N-terminal do eRF3a possam ser altamente relevantes para a integridade celular. Para 
avaliar o efeito da variação do número de glicinas presentes no terminal amina do eRF3a foram 
analisados vários tipos de linhas celulares, expressando os diferentes alelos (GGC)n, e 
comparada a eficiência das proteínas codificadas, nas suas várias funções.  
Dado que a função canónica do eRF3a é como factor de terminação da tradução, utilizou-se a 
linha celular HEK293, que contém um gene repórter com um codão stop prematuro, para 
comparar a eficiência das proteínas na terminação da tradução. Sendo o gene repórter o da β-
galactosidase, a determinação da quantidade desta proteína activa nas células reflete o nível de 
readthrough do codão SOPT prematuro no respectivo gene. Através da quantificação dos níveis 
de readthrough em células expressando proteínas eRF3a com 7-12 resíduos de glicina no 
terminal amina não foram detectadas diferenças significativas de eficiência entre as proteínas de 
diferentes tamanhos.  
Para além de outras funções relacionadas com o processo de tradução, sabe-se que o eRF3a está 
envolvido na passagem da fase G1 para a fase S do ciclo celular e também no controlo da 
apoptose. Apesar de, em ambos os casos, as vias em que o eRF3a participa não estarem ainda 
identificadas, pretendeu-se avaliar se proteínas com diferentes tamanhos poderiam ter 
eficiências diferentes nas funções que desempenham nas respectivas vias. Para tal, recorreu-se 
à citometria de fluxo de forma a determinar as taxas de proliferação e de apoptose em linhas 
primárias de linfócitos e em células Jurkat transformadas, expressando os cinco alelos diferentes. 
No entanto, não foram detectadas diferenças significativas entre as linhas celulares 
relativamente a qualquer dos parâmetros analisados quer em relação a índices de proliferação, 
quer no que diz respeito a taxas de apoptose.  
Está descrito que, em diferentes espécies, alterações de expressão ou mutações no gene eRF3 
levam a malformações do fuso acromático, erros na segregação dos cromossomas durante a 
meiose, e bloqueio da citocinese. Sendo estes eventos potencialmente geradores de um fenótipo 
maligno, pretendeu-se averiguar se o tamanho da proteína teria alguma influência no seu papel 
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de regulação do citoesqueleto. Através da realização de um teste de micronúcleos com bloqueio 
da citocinese (CBMN assay), foi determinada a frequência de micronúcleos (MN) em células 
binucleadas, em linhas celulares com diferentes genótipos. Os nossos resultados demonstram 
que as linhas celulares que expressam alelos mais longos, especificamente as que expressam o 
alelo 12GGC, apresentam maiores frequências de MN em células binucleadas, possivelmente 
como resultado de defeitos na formação do fuso acromático. Em consequência, é de prever que 
ocorra uma acumulação de erros a nível dos cromossomas, característica de células cancerígenas, 
levando à promoção da tumorigenese. 
Apesar do envolvimento do gene eRF3a/GSPT1 no desenvolvimento de cancro não estar ainda 
totalmente esclarecido, os nossos resultados indicam que a presença do alelo 12GGC por si só 
poderá ser considerado como marcador de susceptibilidade para o desenvolvimento de cancro. 
Uma melhor compreensão dos mecanismos de regulação da expressão do gene eRF3a/GSPT1 e a 
sua associação com a proliferação celular poderá também contribuir para progressos quer ao 
nível do prognóstico da doença quer a nível de aplicações terapêuticas. Em conclusão, os nossos 
resultados indicam que o gene eRF3a/GSPT1 deve ser considerado um potencial proto-oncogene. 
Espera-se que, no seu todo, esta dissertação tenha contribuído para o desenvolvimento de 
futuras investigações sobre a regulação da expressão do gene eRF3a/GSPT1 e a sua contribuição 
na génese tumoral e possa vir a melhorar o nosso conhecimento sobre o diagnóstico, 
prognóstico e tratamento de cancro. 
 
 
 
Palavras chave: eRF3a/GSPT1, cancro, expansão GGC, expressão génica, proto-oncogene 
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ABSTRACT 
 
 
 
The eukaryotic release factor 3 (eRF3) associates with eRF1 in a complex that mediates 
translation termination. In addition to its roles in translation, eRF3 is also involved in cell cycle 
regulation, apoptosis and cytoskeleton assemble. Human eRF3 has two distinct isoforms, eRF3a 
and eRF3b, encoded by eRF3a/GSPT1 and eRF3b/GSPT2 genes. 
eRF3a/GSPT1 contains a stable (GGC)n expansion coding for proteins with different N-terminal 
extremities. We identified five alleles encoding 7, 9, 10, 11 and 12 GGC repeats in the 
Portuguese population, being the 10GGC allele the most frequent (F= 68.5% in the control 
population). The longer allele (12GGC) was exclusively detected in 5.1% of the cancer patients 
(N=411) with an allele frequency of 3%, corresponding to a 12-fold increased cancer risk.  
Our results show that the mRNA levels of eRF3a/GSPT1 are overexpressed in a significant 
proportion of different types of cancer. Moreover, the transcript levels of eRF3a/GSPT1 show 
variation between alleles, being the 12GGC allele significantly overexpressed (p<0.001). The 
levels of eRF3a/GSPT1 transcription are not associated with eRF3a/GSPT1 amplification neither 
with the methylation pattern of the GGC expansion region.  
Using an in vivo assay for readthrough efficiency, we do not detect any difference in the activity 
of the eRF3a proteins encoded by the five different eRF3a/GSPT1 alleles. Also, no differences in 
the levels of apoptosis and proliferation rates were found between cells lines. Finally, using a 
cytokinesis-block micronucleos assay, we show that cells with the longer alleles have higher 
frequencies of MN, which is probably a result of defects in mitotic spindle formation.  
Although the connection between eRF3a/GSPT1 and tumorigenesis is not completely elucidated, 
our data suggests that the presence of the 12GGC allele provides a novel risk marker for cancer. 
Taken together, our results show that eRF3a should be considered as a potential proto-oncogene. 
 
 
 
Key-words: eRF3a/GSPT1, cancer, GGC repeats, gene expression, proto-oncogene  
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1. CHAPTER I 
INTRODUCTION 
 
 
 
1.1. Identification of eRF3 
 
Long before the identification of the eukaryotic Release Factor 3 (eRF3), it was known that the 
translation termination process in eukaryotes was GTP-dependent. However, no GTP binding 
motif was identified in eRF1, the main factor acting in translation termination, which suggested 
the existence of an additional unidentified protein involved in the process. This suspicion was 
further reinforced by the knowledge of the prokaryotic termination factor RF3, which has no 
release activity by itself, being a GTP stimulator of the termination step of translation 
(Zhouravleva et al., 1995).  
In 1988, the Japanese group from Kikuchi isolated a new temperature sensitive mutant strain of 
Saccharomyces cerevisae, gst1 (G-to-S transition), which affected the G1-to-S phase transition 
of the cell cycle. A DNA clone complementing the gst1-1 mutation was isolated from a yeast 
gene library and the gene product was a protein of ~76 KDa which contained consensus 
sequence for GTPases and had extensive homology to polypeptide chain elongation factor 
EF1α (Kikuchi et al., 1988). In the same year, Kushnirov’s group in Russia cloned the sup35 gene 
(also named SUP2) from S. cerevisae when looking for omnipotent suppressor mutants. 
Mutations in both GST1 and SUP35 increased the level of translation ambiguity, suggesting that 
the gene product could be a regulator of translation accuracy. Both turned out to be the same 
gene. One year later, the Japanese group cloned the human homologue gene (GST1-Hs) from 
the cDNA library of human KB cells (Hoshino et al., 1989). This gene was latter renamed GSPT1 
and mapped on human chromosome 16p13.1 (Ozawa et al., 1992). In this study, the authors 
also showed the existence of a homologous gene on the X chromosome.  
In 1995, it was demonstrated that the Sup-35 like protein from Xenopus laevis directly interacts 
with the Sup45 (eRF1) and enhances its activity in a GTP-dependent manner (Zhouravleva et al., 
1995). Thus, the gene product was finally named eRF3, following the nomenclature from the 
prokaryote factors.   
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Later, Hoshino et al. (1998) isolated two mouse GSPT genes, the counterpart of human GSPT1 
and a novel member of the family, GSPT2. Both protein products interact with eRF1 to function 
as eRF3 in mammalian translation termination. Subsequently, the human GSPT2 gene has been 
mapped in Xp11.21-23 (Hansen et al., 1999), and the protein encoded characterized and 
described as eRF3b (Jakobsen et al., 2001). 
Despite the diversity of names that were given to these genes and encoded proteins during the 
past two decades, it is now consensual to call eRF3a and eRF3b to the mammalian proteins, and 
eRF3a/GSPT1 and eRF3b/GSPT2 to the respective genes. This is the terminology that will be 
used in the present dissertation.   
 
 
1.2. Characterization of human eRF3’s genes and proteins 
 
Human eRF3 has two distinct isoforms, eRF3a and eRF3b, encoded by eRF3a/GSPT1 and 
eRF3b/GSPT2 genes, located in 16p13.1 (Ozawa et al., 1992) and Xp11.21-23 (Hansen et al., 
1999), respectively. It was recently proposed that eRF3b/GSPT2 was originated through 
retrotransposition of processed eRF3a/GSPT1. The putative eRF3b/GSPT2 retroposon included a 
copy of the endogenous eRF3a/GSPT1 5’UTR sequence, therefore being a functional retrogene 
(Zhouravleva et al., 2006). 
eRF3a/GSPT1 contains 15 exons and spans along 43,27Kb in chromosome 16p (Figure 1). 
Although the promoter region(s) remains to be characterized, there are two alternative initiation 
codons identified. Even so, it was demonstrated that translation is initiated at the first AUG 
encountered at the 5' end of eRF3a/GSPT1 (Jean-Jean et al., 1996). The corresponding mRNA 
(Accession Number: NM_002094; 2585 bp) is ubiquitously expressed in all tissues, and its level 
varies during the cell cycle, being its expression inducible under growth stimulation (Hoshino et 
al., 1998).  
 
Figure 1: Transcript structure of eRF3a/GSPT1 
(Src: http://www.ensembl.org/Homo_sapiens/geneview?gene=ENSG00000103342) 
 
 
eRF3b/GSPT2 is an intronless gene that lies upon 2,5Kb in chromosome Xp (Figure 2). 
eRF3b/GSPT2 mRNA (NM_018094; 2503 bp) is poorly expressed in most mouse tissues tested 
except the brain, and does not fluctuate during the cell cycle (Hoshino et al., 1998). It’s 
expression in human tissues is still not clearly characterized.  
16p13.1 
reverse strand 43.27 Kb 
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Figure 2: Transcript structure of eRF3b/GSPT2 
(Src: http://www.ensembl.org/Homo_sapiens/geneview?gene=ENSG00000189369) 
 
 
The coding sequence of both genes share 88% homology, being the most important difference in 
the nucleotide sequences the presence of a GGC expansion close to the initiation codon in 
eRF3a/GSPT1 that eRF3b/GSPT2 lacks.  
The eRF3 proteins consist of three main regions, a non-homologous amino (N) terminal domain 
(~200 residues), a middle (M) domain, and a conserved EF1α-like carboxyl (C) terminal domain 
of 428 residues (see Figure 3 for details). The three domains were defined based on amino acid 
features and functions. The amino acid sequence of the human eRF3a protein (Hoshino et al., 
1989) presents extensive homology with other eukaryotes like the Xenopus laevis (Zhouravleva 
et al., 1995), Sacaromices cerevisae (Kushnirov et al., 1988), Pinchia pinus (Kushnirov et al., 
1990), Mus musculus (Hoshino et al., 1998) and Podospora anserina (Gagny & Silar, 1998). All 
these proteins exhibit GTP-binding motifs in the C-terminal domain, which is similar to EF1α 
(Kushnirov et al., 1988) and to the prokaryotic RF3 (Grentzmann et al., 1994). However, 
eukaryotic eRF3 and the prokaryotic counterpart have a distinctive feature: the gene encoding 
the prokaryotic RF3 is nonessential (Grentzmann et al., 1994) while at least the C-domain of the 
eukaryotic eRF3 has been shown to be essential for cell viability in different species, including 
Homo sapiens (Kushnirov et al., 1988; Gagny & Silar, 1998; Frolova et al., 1996). 
The C-terminal region of eRF3 proteins is highly conserved through evolution, and carries the 
four canonical GTP-binding motifs of the GTPase superfamily. The N-terminal region varies in 
both length and sequence among species.  
 
 
 
 
Xp11.21-23 
forward strand 2.5 Kb 
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Figure 3: Schematic representation of the eRF3 family. Proteins belonging to the eRF3 family could 
be divided into three regions: an amino terminal non-conserved region (N), a median domain (M) of 
unknown function and a homologous C-terminal domain (C). 
h: H. sapiens; m: M. musculus; y: S. cerevisae; x: Xenopus laexis. 
 
 
The human eRF3a and eRF3b protein sequences are about 87% identical (Figure 4) being the 
differences in amino acid sequence concentrated near the amino terminus. The N-domain of 
eRF3a is rich in acidic amino acids and contains a high percentage of Pro, Ser and Gly residues 
(10%, 15% and 20%, respectively). Also, eRF3a includes a stable polyglycine expansion 
encoded by a (GGC)n tract in eRF3a/GSPT1 gene, with five different known alleles (Riggins et al., 
1992; see chapter  1.5 for details). eRF3a is abundant in all tissues, while eRF3b expression 
pattern still needs further elucidation, although it was reported to be absent in the majority of 
human cell lines tested (Chauvin et al., 2005).  
From the first functional studies reported, the C-terminal domain of eRF3 has been described as 
essential for eRF1 binding and sufficient for the protein’s role as a translation termination factor, 
while the N-terminal domain remained poorly understood (Ter-Avanesyan et al., 1993; 
Zhouravleva et al., 1995; Kisselev & Frolova, 1995; Mugnier & Tuite, 1999) being sometimes 
viewed as functionally nonessential (Merkulova et al., 1999). 
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1.3. Functions of eRF3a 
 
1.3.1. The canonical role of eRF3a in translation termination 
 
Eukaryotic translation termination is governed by two release factors, eRF1 and eRF3. These 
factors associate in a complex which binds to the ribosomal A site. eRF1 is the key factor of 
translation termination, recognising the three stop codons in the mRNA (UAA, UAG and UGA), 
catalyzing the ester bond hydrolysis of the peptidyl-tRNA and promoting the release of the 
nascent peptide chain. eRF3 is a small GTPase protein that enhances eRF1 activity (Zhouravleva 
et al., 1995).  
Hoshino et al. (1998) demonstrated that both mammalian eRF3a and eRF3b can interact with 
eRF1. Surprisingly, it was reported later that mouse eRF3b, but not eRF3a, could substitute for 
yeast eRF3 in vivo (Le Goff et al., 2002), which possible means that in mammalian cells eRF3a 
and eRF3b share the multiple functions fulfilled by yeast’s eRF3 (Inge-Vechtomov et al., 2003).     
GTP hydrolysis is required for fast and efficient termination of translation (Mitkevich et al., 2006). 
It was demonstrated that eRF3 is a GTP-binding protein capable of a negligible, if any, intrinsic 
GTPase activity that is greatly stimulated by the joint action of eRF1 and the ribosome (Salas-
Marco & Bedwell, 2004). Neither eRF1 nor the ribosome displays this effect de per se (Frolova et 
al., 1996). Thus, eRF3 functions as a GTPase in the quaternary complex with the ribosome, eRF1, 
and GTP. Binding of eRF3 to eRF1, as revealed in vivo and in vitro (Stansfield et al., 1995; 
Zhouravleva et al., 1995), is mediated by the C-terminal domains of both proteins (Ebihara & 
Nakamura, 1999; Merkulova et al., 1999; Kononenko et al., 2008). This finding was further 
reinforced by Chauvin et al. (2005) observations that X. laevis eRF3, which is highly homologous 
to eRF3b in its N-terminal extension, can substitute for human eRF3a. In contrast, neither the 
entire S. cerevisiae eRF3, which is highly divergent from human and Xenopus eRF3’s in the N-
terminal domain, nor the N-terminally truncated form of S. cerevisiae eRF3 carrying the 
conserved C terminal domain only, efficiently substitutes eRF3a in termination. The crystal 
structure of the eEF1α−like region of eRF3 from S. pombe led to the identification of the eRF1 
binding region (Figure 4) and revealed that the N-terminal extension, rich in acidic amino acids, 
can block the proposed eRF1 binding site, potentially regulating eRF1 binding to eRF3 in a 
competitive manner (Kong et al., 2004). 
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h_eRF3a  MDPGSGGGGG GGGGGGSSSG SSSSDSAPDC WDQADMEAPG PGPCGGGGS- ---LAAA--- AEAQRENLSA 
m_eRF3a  MDPSSGGGGG GGGGGSSSS- ---SDSAPDC WDQTDMEAPG PGPCGGGGSG SGSMAAV--- AEAQRENLSA
h_eRF3b  M--------- -------DSG SSSSDSAPDC WDQVDMESPG SAPSGDGVS- ----SAV--- AEAQREPLSS 
m_eRF3b  M--------- -------DLG SSS-DSAPDC WDQVDMEAPG SAPSGDGIAP AAMAAAEAAE AEAQRKHLSL
Sc_eRF3  M---SDSNQG NNQQNYQQYS QNGNQQQGNN RYQGYQAYNA QAQPAGGYYQ NYQGYSGYQQ GGYQQYNPDA
h_eRF3a  AFSRQLNVNA KPFVPNVH-- -AAEFVP--- -----SF--- --LRG----- PAAPP–PPVG GAANN--HGA
m_eRF3a  AFSRQLNVNA KPFVPNVH-- -AAEFVP--- -----SF--- --LRG----- PAQPPLSPAG AAGGD--HGA
h_eRF3b  AFSRKLNVNA KPFVPNVH-- -AAEFVP--- -----SF--- --LRG----- PTQPPTL-PA GSGSNDETCT 
m_eRF3b  AFSSQLNIHA KPFVPSVS-- -AAEFVP--- -----SF--- --LPG----- SAQPPAPTAS SCDETCIGGA
Sc_eRF3  GYQQQYNPQG GYQQYNPQGG YQQQFNPQGG RGNYKNFNYN NNLQGYQAGF QPQSQGMSLN DFQKQQKQAA
h_eRF3a  GSGAGG-R-- ---AAPVESS QEEQSL-C-E G--SNSAVSM ELSEPIVENG ETE--MSPEE SWEHKEEISE
m_eRF3a  GSGAGG-P-- ---SEPVESS QD-QS--C-E G--SNSTVSM ELSEPVVENG ETE--MSPEE SWEHKEEISE
h_eRF3b  GAGYPQ-GKR MGRGAPVEPS REEPLVSL-E G--SNSAVTM ELSEPVVENG EVE--MALEE SWEHSKEVSE
m_eRF3b  GEPEGK-RME --WGAPVEPS KDGPLVS-WE G--SSSVVTM ELSEPVVENG EVE--MALEE SWEL-KEVSE
Sc_eRF3  PKPKKTLKLV SSSGIKLANA TKKVGTKPAE SDKKEEEKSA ETKEPTKEPT KVEEPVKKEE KPVQTEEKTE
h_eRF3a  AE---PGGGS LGDGRPPEES AHEMMEEEEE IPKPKSVVAP PGAPK----- KEHVNVVFIG HVDAGKSTIG
m_eRF3a  AE---PGGGS SGDGRPPEES TQEMMEEEEE IPKPKSAVAP PGAPK----- KEHVNVVFIG HVDAGKSTIG
h_eRF3b  AE---PGGGS SGDSGPPEES GQEMMEEKEE IRKSKSVIVP SGAPK----- KEHVNVVFIG HVDAGKSTIG
m_eRF3b  AK---PEA-S LGDAGPPEES VKEVMEEKEE VRKSKSVSIP SGAPK----- KEHVNVVFIG HVDAGKSTIG
Sc_Erf3  EKSELPKVED LKISESTHNT NNANVTSADA LIKEQEEEVD DEVVNDMFGG KDHVSLIFMG HVDAGKSTMG
h_eRF3a  GQIMYLTGMV DKRTLEKYER EAKEKNRETW YLSWALDTNQ EERDKGKTVE VGRAYFETEK KHFTILDAPG
m_eRF3a  GQIMYLTGMV DKRTLEKYER EAKEKNRETW YLSWALDTNQ EERDKGKTVE VGRAYFETEK KHFTILDAPG
h_eRF3b  GQIMFLTGMV DKRTLEKYER EAKEKNRETW YLSWALDTNQ EERDKGKTVE VGRAYFETEK KHFTILDAPG
m_eRF3b  GQIMFLTGMV DRRTLEKYER EAKEKNRETW YLSWALDTNQ EERDKGKTVE VGRAYFETEK KHFTILDAPG
Sc_eRF3  GNLLYLTGSV DKRTIEKYER EAKDAGRQGW YLSWVMDTNK EERNDGKTIE VGKAYFETEK RRYTILDAPG
h_eRF3a  HKSFVPNMIG GASQADLAVL VISARKGEFE TGFEKGGQTR EHAMLAKTAG VKHLIVLINK MDDPTVNWSN
M_eRF3a  HKSFVPNMIG GASQADLAVL VISARKGEFE TGFEKGGQTR EHAMLAKTAG VKHLIVLINK MDDPTVNWSN
h_eRF3b  HKSFVPNMIG GASQADLAVL VISARKGEFE TGFEKGGQTR EHAMLAKTAG VKHLIVLINK MDDPTVNWSI
m_eRF3b  HKSFVPNMIG GASQADLAVL VISARKGEFE TGFEKGGQTR EHAMLAKTAG VKYLIVLINK MDDPTVDWSS
Sc_eRF3 HKMYVSEMIG GASQADVGVL VISARKGEYE TGFERGGQTR EHALLAKTQG VNKMVVVVNK MDDPTVNWSK
h_eRF3a  ERYEECKEKL VPFLKKVGFN PKKDIHFMPC SGLTGANLKE QSD--FCPWY IGLPFIPYLD NLPNFNRSVD
m_eRF3a  ERYEECKEKL VPFLKKVGFN PKKDIHFMPC SGLTGANLKE QSD--FCPWY IGLPFIPYLD NLPNFNRSVD
h_eRF3b  ERYEECKEKL VPFLKKVGFS PKKDIHFMPC SGLTGANIKE QSD--FCPWY TGLPFIPYLD NLPNFNRSID
m_eRF3b  ERYEECKEKL VPFLKKVGFS PKKDIHFMPC SGLTGANIKE QSD--FCPWY TGLPFIPYLD SLPNFNRSID
Sc_eRF3  ERYDQCVSNV SNFLRAIGYN IKTDVVFMPV SGYSGANLKD HVDPKECPWY TGPTLLEYLD TMNHVDRHIN
h_eRF3a  GPIRLPIVDK YKDMGTVVLG KLESGSICKG QQLVMMPNKH NVEVLGILSD DVE-TDTVAPG ENLKIRLKGI
m_eRf3a  GPIRLPIVDK YKDMGTVVLG KLESGSICKG QQLVMMPNKH NVEVLGILSD DVE-TDSVAPG ENLKIRLKGI
h_eRF3b  GPIRLPIVDK YKDMGTVVLG KLESGSIFKG QQLVMMPNKH NVEVLGILSD DTE-TDFVAPG ENLKIRLKGI
m_eRF3b  GPIRLPIVDK YKDMGTVVLG KLESGSIFKG QQLVMMPNKH SVEVLGIVSD DAE-TDFVAPG ENLKIRLKGI
Sc_eRF3  APFMLPIAAK MKDLGTIVEG KIESGHIKKG QSTLLMPNKT AVEIQNIYNE TENEVDMAMCG EQVKLRIKGV
h_eRF3a  EEEEILPGFI LCDPNNLCHS GRTFDAQIVI IEHKSIICPG YNAVLHIHTC IEEVEITALIC LVDKKSGEKS
m_eRF3a  EEEEILPGFI LCDLNNLCHS GRTFDAQIVI IEHKSIICPG YNAVLHIHTC IEEVEITALIC LVDKKSGEKS
h_eRF3b  EEEEILPGFI LCDPSNLCHS GRTFDVQIVI IEHKSIICPG YNAVLHIHTC IEEVEITALIS LVDKKSGEKS
m_eRF3b  EEEEILPGFI LCEPSNLCHS GRTFDVQIVI IEHKSIICPG YNAVLHIHTC IEEVEITALIS LVDKKSGEKS
Sc_eRF3  EEEDISPGFV LTSPKNPIKS VTKFVAQIAI VELKSIIAAG FSCVMHVHTA IEEVHIVKLLH KLEKGTNRKS
h_eRF3a  KTRPRFVKQD QVCIARLRTA GTICLETFKD FPQMGRFTLR DEGKTIAIGK VLKLVPEKD  637
m_eRF3a  KTRPRFVKQD QVCIARLRTA GTICLETFKD FPQMGRFTLR DEGKTIAIGK VLKLVPEKD  636
h_eRF3b  KTRPRFVKQD QVCIARLRTA GTICLETFKD FPQMGRFTLR DEGKTIAIGK VLKLVPEKD  628
m_eRF3b  KTRPRFVKQD QVCIARLRTA GTICLETFKD FPQMGRFTLR DEGKTIAIGK VLKLVPEKD  632
Sc_eRF3  KKPPAFAKKG MKVIAVLETE APVCVETYQD YPQLGRFTLR DQGTTIAIGK IVKIAE--- 685
G1
G2
G4
G3
 
Figure 4: Alignment of the amino acid sequences of human and mouse eRF3a and eRF3b and S. 
cerevisae eRF3 proteins. The eRF3 protein family is characterized by a non-homologous amino-
terminal domain, and a conserved EF1α-like C-terminal domain of 428 residues. The start of the EF1α-
like domain is shown in a vertical line. This domain is subdivided in the G domain (amino acid residues 
in grey) and the C-terminal domain. The conservative G1-G4 consensus sequences involved in GTP 
binding are indicated by shadow boxes. The consensus sequence for PABP interaction 
(RQLNVNAKPFVP) is indicated in a dotted line box; the IAP-binding motif (AKPF) is underlined, inside 
the box. The consensus sequence for eRF1 interaction (GRFTLRD) is indicated in a round box. 
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It was recently reported that the DEAD-box RNA helicase and mRNA export factor DBP5 controls 
the eRF3-eRF1 interaction and thus eRF3-mediated downstream events (Gross et al., 2007). 
DBP5 is reported to be required for efficient stop-codon recognition, directly binding to eRF1 to 
remodel the mRNA/protein complex to allow proper eRF1 positioning on the stop codon. 
Subsequent dissociation of DBP5 from eRF1 is followed by the entry of eRF3 into the complex. 
The precise mechanism by which eRF1 and eRF3 promote translation termination when a stop 
codon reaches the A site of the ribosome is still not completely elucidated. It is generally 
accepted that the mechanism is comparable with the elongation system, which is much better 
characterized: eRF1 structurally mimics the stem of an aminoacil-tRNA, whereas eRF3 mimics 
the function of an EF1α, which carries the aminoacil-tRNA to the A site in a GTP-dependent 
manner (Nakamura & Ito, 1998; Hoshino et al., 1998; Inge-Vechtomov et al., 2003). This model 
is consistent with the knowledge that only the EF1α−like C-domain of eRF3 is required for eRF1 
interaction. 
 
1.3.2. Other roles in translation 
 
There is a functional conservation of eRF3 family from yeast to human proteins in what concerns 
its role as a release factor in translation termination. However, the differences in the amino 
domain of the eRF3 revealed interactions with several different proteins, pointing out the 
involvement of eRF3 in several cellular pathways. 
When searching for new eRF3a binding proteins, Hoshino et al. (1999a) identified the 
polyadenylate-binding protein (PABP), whose amino extremity associates with the poli(A) tail of 
mRNAs. Both eRF3a and eRF3b directly interact with PABP via its amino terminal domains, 
through the carboxyl domain of PABP. This interaction results in the inability of PABP to 
multimerize and consequently inhibits it to perform the typical regularly spaced complexes on 
the poli(A) tail of mRNAs that regulate mRNA degradation. This may facilitate shortening of the 
poly(A) tail of mRNAs by an RNase (Hoshino et al., 1999a; Hoshino et al., 1999b; Hosoda et al., 
2003). The PABP also mediates mRNA circularization through binding the eIF4F translation 
initiation complex, which is associated with the mRNA 5’ cap structure (Kozlov et al., 2001). 
Therefore, the termination of translation might regulate the next initiation step via the eRF3-
PABP-eIF4G signalling cascade. These studies revealed that eRF3a may play an important role in 
mRNA stability, as an initiator of the mRNA degradation machinery, and/or in the recycling of 
ribosomes in successive cycles of translation (Hoshino et al., 1999a; Hoshino et al., 1999b; 
Uchida et al., 2002).  
Another role of eRF3 in mRNA degradation, through the nonsense-mediated mRNA decay (NMD) 
pathway, was revealed by Czaplinski et al. (1998). The NMD pathway is a process that rids the 
cell out of transcripts that contain premature termination codons (PTCs). The biological and 
medical significance of NMD is highlighted by an increasing number of known genetic diseases 
that are caused by C-terminally truncated proteins that may be non-functional or could exert a 
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toxic effect in a dominant-negative manner (Holbrook et al., 2004; Kuzmiak & Maquat, 2006; 
Diop et al., 2007). Three core factors involved in NMD have been identified (UPF1, UPF2 and 
UPF3), but several other proteins are known to be involved in this pathway. It was demonstrated 
that these three UPF proteins and both release factors, eRF1 and eRF3, function as part of a 
“surveillance complex” that recognizes PTCs and triggers NMD in S. cerevisae. Direct interactions 
between UPF proteins and eRF1 and eRF3 were demonstrated in vitro (Czaplinski et al., 1998) 
and in vivo (Kobayashi et al., 2004).  
Although the GTPase activity of eRF3 is not necessary for its binding with both UPF1 and PABP, 
the GTP/eRF3-dependent termination exerts direct influence on the subsequent mRNA 
degradation (Kobayashi et al., 2004).  
In mammalian cells, translation termination codons context and exon–exon junctions are cis-
acting elements that allow recognition of stop codons. Recently, Kashima et al. (2006) showed 
that the recognition of PTCs occurs in a complex named SURF (SMG1–UPF1–eRF1–eRF3 
complex) associated with the EJC (exon junction complex) on mRNPs. The presence of 
translation termination factors eRF1 and eRF3 suggested that transient formation of SURF 
complex most likely occurs after recognition of the stop codon, and that the eRF1–eRF3 complex 
probably recruits UPF1 and SMG-1 to a PTC. The SURF associates with the post-splicing mRNA 
through UPF2–EJC to form the DECID (decay-inducing complex). Subsequent UPF1 
phosphorylation finally leads to mRNA degradation (Behm-Ansmant & Izaurralde, 2006; Kashima 
et al., 2006).  
This model was later considered simplistic because different alternative pathways were reported 
(Ivanov et al., 2008). The most recent publications suggest that the recognition of a PTC is 
mediated by competition between the 3’ UTR–associated factors, being the PABP a human NMD 
antagonizing factor inhibiting the interaction between eRF3 and UPF1 in vitro (Amrani et al., 
2006; Eberle et al., 2008; Singh et al., 2008). The NMD appears to be triggered by a ribosome’s 
failure to terminate adjacent to a properly configured 3’-UTR (untranslated region), an event that 
may promote binding of the UPF/NMD factors to stimulate mRNA decapping. The physical 
distance between the stop codon and the PABP is considered a crucial determinant for PTC 
recognition. NMD can only take place when an extended 3’ UTR places PABP distally to the 
termination codon, leaving a downstream exon junction complex in between. The EJC acts 
enhancing NMD, likely through increasing the affinity of UPF proteins. 
Although the precise model is still a matter of controversy, eRF3 plays a central role in the 
process of triggering mRNA decay upon the recognition of a termination codon, being part of a 
transient complex involved in the process.  
 
The outstanding feature of eRF3 is its ability to interact with many other factors, relevant or not 
to the translational machineries (summarized in Table 1). Therefore, it is tempting to speculate 
that eRF3 plays a molecular hub to regulate the translation termination complex functionality 
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through binding to a repertoire of cellular factors or to couple translation termination to other 
divergent cellular processes. 
 
 
Table 1: Properties of known eRF3-binding proteins. 
 
Binding domain 
on eRF3
eRF1 CTD translation termination mammalian Hoshino et al ., 1998
Mtt1 CTD helicase S. cerevisiae Czaplinski et al. , 2000
Upf1 CTD mRNA survaillence human Ivanov et al. , 2008
Upf2, Upf3 CTD mRNA survaillence S. cerevisiae Wang et al., 2001
Ask1 unkown apoptosis regulator human Lee et al. , 2008
Cct subunits unkown chaperonin mammalian King et al ., 2000
cIAP1 (BIRC2) NTD inhibitor of apoptosis human Hedge et al. , 2003
cIAP2 (BIRC3) NTD inhibitor of apoptosis human Hedge et al ., 2003
Itt1 NTD Unknown S. cerevisiae Urakov et al ., 2001
Pabp1 NTD Poly(A) binding human Hoshino et al ., 1999a
RnaseL NTD Rnase human Le Roy et al ., 2005
Sla1 NTD actin assenbly S. cerevisiae Bailleul et al ., 1999
Xiap NTD inhibitor of apoptosis human Hedge et al., 2003
Gene Function Species Reference
 
NTD: N-terminal domain; CTD: C-terminal domain 
 
 
1.3.3. Cytoskeleton assembly 
 
The cytoskeleton is a cytoplasmatic dynamic and complex network of filaments responsible for 
cell movement, shape, intracellular transport and cellular division, composed essentially of actin 
filaments, tubulin microtubules and intermediate filaments in the cytoplasm (Honore et al. 2005). 
After translation termination, the biogenesis process of some proteins, like actins and tubulins, 
involve interaction of nascent chains with the heterohexameric protein prefoldin (PFDN), whose 
function is to deliver non-native target proteins to the eukaryotic cytosolic chaperonins for 
facilitated folding (Simons et al., 2004) protecting them from aggregation while being transferred 
to chaperonin for the final step(s) in their folding (Vainberg et al., 1998). The target proteins are 
transferred by PFDN to the cytosolic chaperonin CCT (chaperonin containing TCP-1), which is a 
hetero-oligomeric complex with double-ring-like structure showing eightfold rotational symmetry 
of eight different subunits in mammalian somatic cells. The CCT complex is an important 
pathway that regulates microtubules stability and, consequently, cytoskeleton organization. CCT 
has been shown to assist in the folding of actin and tubulin in the presence of ATP in vitro (Tian 
et al., 1995; Farr et al., 1997) and to bind newly synthesized actin and tubulin in vivo 
(Thulasiraman et al., 1999). Each subunit of the complex recognizes specific target proteins and 
they collectively modulate the ATPase activity (Kubota et al., 1999). 
An interaction between CCT subunits and eRF3 was first predicted using a theoretical model 
(Eisenberg et al., 2000), and experimentally confirmed by immunoprecipitation (King et al., 
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2000; Martin Carden, personal comm). The CCT expression level correlate with growth rates in 
mammalian cultured cells, and is markedly up-regulated in the early S phase of the cell cycle 
(Yokota et al., 1999). Interestingly, the eRF3 protein is also essential for G1 to S phase 
transition of the cell cycle (Hoshino et al., 1998; Chauvin et al., 2007). 
Using different organisms as study models, eRF3 has been shown to affect both tubulin and actin 
cytoskeleton. Deregulation of eRF3 expression and/or mutations in the N-terminal domain of the 
protein resulted in abnormal meiotic chromosome segregation and defects in the cytoskeleton 
assembly in spermatids of Drosophila melanogaster (Basu et al., 1998). In S. cerevisiae, eRF3 is 
also involved in regulatory interactions with intracellular structural networks, through 
interactions with the yeast cytoskeletal assembly protein SLA1, via its N-terminal domain 
(Bailleul et al., 1999). The eRF3 was also shown to affect the tubulin cytoskeleton, suggesting a 
role in the control of chromosome segregation at the anaphase (Borhsenius et al., 2000). More 
recently, its involvement in the assembly of the actin cytoskeleton in yeast was also 
demonstrated (Valouev et al., 2002), affecting the impairment of the mitotic spindle structure 
and chromosome segregation. Chai et al. (2006) showed that the eRF3 is distributed around the 
macronucleus and in the basal bodies in the cortex of Euplotes octocarinatus cells, suggesting 
that this protein may be involved in cytoskeleton organization.  
From these studies, it is not clear whether the aberrant phenotypes reported are either an 
indirect consequence of disruptions of translation caused by deficient activity of eRF3 in 
translation termination, or, instead, reflect a more direct interaction of this protein with the 
microtubule cytoskeleton. 
 
1.3.4. Apoptosis regulation 
 
A proteolytically processed isoform of the eRF3a protein was reported to function as an inhibitor 
of apoptosis binding proteins (IAP-BPs) (Hedge et al., 2003; Verhagen et al., 2007). IAP-BPs are 
a group of proteins characterized by the presence of a conserved 4-residue IAP-binding motif 
(IBM) at their N termini, which allows them to bind to the Baculovirus IAP Repeat (BIR) domain 
of IAPs. The processed eRF3a protein contains the conserved N-terminal IAP-binding motif 
(AKPF), which is exposed after proteolytic cleavage of a 69-residue leader sequence (Figure 4). 
eRF3 directly interacts with IAPs (such as cIAP1, cIAP2 and XIAP), and can promote caspase 
activation, IAP ubiquitination and apoptosis (Hegde et al., 2003). In the model proposed, eRF3a 
could potentiate apoptosis by liberating caspases from IAP inhibition, and/or target IAPs and the 
processed eRF3a for proteasome-mediated degradation. Interestingly, the authors also 
demonstrated that the processed protein localized in both the cytoplasm and nuclear 
compartments of MCF-7 cells, suggesting that its association with the endoplasmic reticulum 
(ER) (which was expected and confirmed for the normal complete protein) is disrupted by 
deletion of its N terminus.  
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Two possible explanations for these findings were suggested: the processing of eRF3a might be 
triggered by ER stress or other cellular stress conditions or, alternatively, could be a regulatory 
mechanism to modulate the protein levels during the cell cycle by targeting it for proteosomal 
degradation via the IAP pathway. The last hypothesis is supported by Chauvin’s et al. (2008) 
results showing that eRF3a is degraded by the proteasome when not associated with eRF1. 
Nevertheless, disturbance of the correct interaction/balance between eRF3a and IAPs can release 
these proteins and consequently repress or even block the apoptosis pathways in which they are 
involved. Conversely, it can promote the apoptosis process targeting the IAPs for degradation. 
Recently, eRF3a was also reported to interact with the apoptosis signal-regulating kinase 1 
(ASK1), a mitogen-activated protein kinase (MAPK) kinase kinase of the c-Jun N-terminal kinase 
(JNK) and p38 MAPK pathways (Lee et al., 2008). ASK1 plays a critical role in mediating 
apoptosis signals initiated by various stresses, such as reactive oxygen species (ROS), 
endoplasmic reticulum (ER) stress, hydrogen peroxide (H2O2) and tumor necrosis factor-α (TNF-
α). Although the authors did not clarify what signal activates eRF3a to regulate ASK1, they 
showed that the processing of eRF3a is not critical for ASK1 binding. In addition, they also show 
that H2O2 and TNF-α have no effect on the transcription of eRF3a/GSPT1. 
 
 
1.4. Cancer 
 
During the past century, the clinical behavior of human cancer has been predicted using its 
histological features. In the 1980s, at the dawn of the era of molecular medicine, researchers 
started to believe that cancer was caused by deregulation of a few oncogenes or tumour-
suppressor genes. In the past decades, substantial progress has been made in discovering 
cancer-associated genes that are altered through point mutations, deletions, amplifications, 
rearrangements or other events. Therefore, it has become clear that human tumours are more 
complex and heterogeneous than expected, and are caused by defects in numerous pathways 
and factors that operate at many levels (Liotta & Petricoin, 2000; Hanash, 2004; Bodmer & 
Bonilla, 2008; Dong et al., 2008).  
Cancer is a genetically and biologically highly heterogeneous disease that likely requires 
individually tailored therapies based on the patient’s individual genetic and biologic alterations. 
The multifactorial process of carcinogenesis involves mutations in oncogenes, or tumor 
suppressor genes, as well as the influence of environmental etiological factors. During the last 
few decades, extensive effort has been invested in identifying sources of genetic susceptibility to 
cancer. Common DNA polymorphisms in low penetrance genes have emerged as genetic factors 
that seem to modulate an individual's susceptibility to malignancy (Fearnhead et al., 2004; 
Kryukov et al., 2007; Iyengar & Elston, 2007; Milne & Benítez, 2008). Both the International 
Human Genome Sequencing Project and the International HapMap Project have generated a very 
large amount of data on the location, quantity, type and frequency of genetic variants in the 
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human genome. A large and increasing number of observational studies investigating the 
association between variants in candidate genes and cancer risk have emerged. Given their 
abundance and stability, single nucleotide polymorphisms (SNPs) hold great promise as markers 
for mapping disease susceptibility loci for common, complex disorders by association studies 
(Bodmer & Bonilla, 2008; Polychronakos, 2008). For this purpose the development of non-
invasive, inexpensive, accurate, high-throughput methods for scoring large numbers of SNPs 
from hundreds of patients and controls is critical.  
Despite the intensive effort devoted to the issue, the ability to detect the genetic components of 
cancer etiology has been very limited. Exceptions include genes that cause rare, mainly 
monogenic family cancer syndromes such as Brca1 and Brca2 in familial breast and ovarian 
cancer (Narod & Foulkes, 2004), Mlh1 and Mlh2 in hereditary nonpolyposis colorectal cancer 
(Plotz et al., 2006), Cdkn2a in familial melanoma (Bishop et al., 2007) and p53 in Li-Fraumeni 
syndrome (Evans & Lozano, 1997; Varley, 2003). However, such exceptions tend to account for 
only a small portion of disease heritability. For example, the breast cancer susceptibility genes 
Brca1 and Brca2 explain only a minority (<30%) of familial breast cancers and a negligible 
proportion of sporadic breast cancers (Narod & Foulkes, 2004). In conclusion, the genetic 
etiology of most cancers remains largely unclear. 
 
Cancer is now a major public health problem in Europe, and the ageing of the European 
population will most certainly cause these numbers to continue to increase. According to the 
World Health Organization (WHO) cancer is the second cause of death in Portugal and so it will 
be until 2030, according to projections based on 2002 WHO burden of disease estimates 
(http://apps.who.int/infobase/report.aspx?iso=PRT&rid=119&goButton=Go). The most common 
incident forms of cancer are breast and prostate cancer for women and men respectively, 
followed by colorectal cancer, lung cancer and stomach cancer in both genders. The same types 
of tumors are within the top five most common causes of cancer deaths (Boyle & Ferlay, 2005; 
Ferlay et al., 2007; Karim-Kos et al., 2008). 
The promise of early detection is that it will identify cancer while still localized and curable, not 
only preventing mortality but also morbidity and health costs. However, despite that our 
knowledge of cancer has increased greatly during the past decades, many of the genetic 
alterations underlying cancer development remain to be clarified. Which of these alterations are 
the key players in the initial development of cancer is still not known in most of the cancer types. 
Moreover, the ability to translate this knowledge into clinical practice remains elusive. 
 
Here follows a brief description of the types of cancer used as models in our research work. 
Breast cancer is the leading cause of cancer in women worldwide (Hinestrosa et al., 2007; Perry 
et al., 2008). Breast tumors vary greatly in clinical behavior, morphological appearance, and 
molecular alterations. In general, the genes that have been identified as being associated with 
hereditary breast cancer (Brca1, Brca2, p53, Chk2, and Atm) are involved in the maintenance of 
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genomic integrity and DNA repair (Narod & Foulkes, 2004). However, less than 10% of women 
who develop breast cancer have an identifiable inherited mutation to the disease, and another 
15%–20% have a family history but no readily identifiable genetic pattern (Easton et al., 2007; 
Hinestrosa et al., 2007). The majority of the women develop somatic tumors, in which any 
known genetic mutation is identified as being the driving force in the origin of the disease. 
Therefore, although much knowledge has been achieved about breast cancer in the past decades, 
it continues to be the leading cause of cancer-related death in women. 
Despite gastric cancer incidence and mortality have decreased over the past decades, it is still 
the second most frequent cause of cancer-related death in the world (Crew & Neugut, 2006). 
Multiple genetic and epigenetic alterations in cell cycle regulators, cell adhesion molecules, DNA 
repair genes and telomerases, as well as genetic instability at microsatellite loci are the most 
common events implicated in the multistep process of gastric carcinogenesis (Tahara, 2004). 
However, gastric cancer is essentially a heterogeneous disease, and the events that underlie the 
malignant transformation of the gastric mucosa during the multistep process of gastric cancer 
pathogenesis remain uncertain (Zheng et al., 2006). Several histological classification for gastric 
cancer have been proposed, being the Lauren’s (1965) classification the most usual - two major 
forms of gastric tumors are distinguished according to their morphological and clinicopathological 
classifications: intestinal (well-differentiated) and diffuse (undifferentiated) type tumors. They 
differ in genetic susceptibility, pathologic profile, clinical presentation, and prognosis (Crew & 
Neugut, 2006; Cervantes et al., 2007). The intestinal type carcinoma is frequently preceded my 
multifocal atrophic gastritis and is more common in elderly man; the tumors show gland 
formation and are usually well demarcated. For the diffuse type tumors the precursor lesions are 
usually not identified and the prognosis is less favorable, they show no cohesiveness of tumors 
cells infiltrating the stroma and occurs preferably in women under 50 years old  (Werner et al., 
2001). Molecular pathology supports this classification by showing differences in the genetics 
pathways in the origin of both kinds of tumors (Werner et al., 2001; Tahara, 2004; Cervantes et 
al., 2007). Nevertheless, the prognosis for patients with advanced gastric cancer remains poor, 
much because gastric cancer is often diagnosed at an advanced stage. Therefore, it is still a 
challenge to detect stage-specific genetic abnormalities that may result in early diagnosis and aid 
in selecting therapy. 
Colorectal cancer (CRC) is the most common cancer in Europe. Approximately 70% of colorectal 
cancers are sporadic, with no inherited predisposition (Shen et al., 2007). Although highly 
penetrant mutations in single genes are known to be responsible for hereditary syndromes, low 
penetrance susceptibility genes account for a high proportion of the tumors (Mecklin, 2008). 
Several subgroups with different precursor lesions and behavior can already be distinguished 
(Shen et al., 2007; Takayama et al., 2007; Li & Lai, 2009). There is heterogeneity in the genetic 
pathways leading to CRCs, and there are two major tumorigenic pathways. The first is driven by 
chromosomal instability (CIN), in which accumulating mutations in genes of K-ras (v-Ki-ras2 
Kirsten rat sarcoma viral oncogene homolog), Apc (adenomatous polyposis coli), p53 (tumor 
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protein P53), and Dcc (deleted in colorectal carcinoma), are thought to be of significance. An 
alternative genetic pathway, related to genetic instability, evolves as a consequence of the 
alteration in mismatch repair (MMR) genes. However, these two distinct pathways are not able to 
account for all CRCs. Moreover, there is still an extend gap between basic research and clinical 
practice, probably due to the genetic and molecular complexity of the tumors (Gil-Bazo, 2007; 
Huerta, 2008; Nannini et al., 2009). Interaction of genetics and environmental effects has an 
important role in colorectal carcinogenesis. High body-mass index, increased meat or alcohol 
consumption and tobacco smoking are examples of confirmed risk factors. A positive family 
history of CRC increases the estimated risk for CRC by 2- to 4-fold (Mecklin, 2008).  
Chronic and persistent inflammation has long been associated with the development of cancer. 
The genetic changes that occur within cancer cells themselves, such as activated oncogenes or 
dysfunctional tumor suppressors, are responsible for many aspects of cancer development but 
they are not sufficient. Tumor promotion and progression are dependent on cells of the tumor 
environment, that are not necessarily cancerous themselves (Rakoff-Nahoum, 2006). Mediators 
of the inflammatory response, e.g., cytokines, free radicals, prostaglandins and growth factors, 
can induce genetic and epigenetic changes, DNA methylation and post-translational modifications, 
causing alterations in critical pathways responsible for maintaining the normal cellular 
homeostasis and leading to the development and progression of cancer (Hussain & Harris, 2007). 
Nowadays, the association between Crohn’s disease (CD) and increased risk for CRC is widely 
accepted (Zisman & Rubin, 2008). Crohn’s disease (CD) is a chronic inflammatory disease that 
can affect the entire gastrointestinal tract from the mouth to the anus. CRC is the most common 
type of cancer in inflammatory bowel disease (IBD), although cancer in other organs can occur. 
Although CRC associated to IBD accounts only for 1%-2% of all cases of CRC in the general 
population, it is considered a serious complication of this disease and accounts for approximately 
10%-15% of all deaths in IBD patients (Munkholm, 2003). Several of the molecular alterations 
that contribute to sporadic CRC are also found in IBD-associated CRC (Zisman & Rubin, 2008). 
CD is therefore a complex disease in which multiple genetic and environmental factors are likely 
to contribute to pathogenesis, and the search for CD susceptibility genes therefore poses similar 
problems to those in other complex disorders, like cancer. 
Despite these types of cancer are of the most prevalent cancer types in the world today, only a 
limited number of biomarkers are available for detection and prognostic evaluation. New 
advances in identifying molecular biomarkers are essential. The intricate nature of the 
contributions of many factors ultimately determines the impact that a particular alteration has on 
the properties of a tumour or a precursor lesion (Hanash, 2004). In the future, cancer screening 
tests will probably combine the result of multiple diagnostic tests and biomarker assays with 
patient’s specific risk factors. 
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1.4.1. Translation and cancer 
 
Regulation of translation plays a major role in the control of eukaryotic gene expression 
(Gebauer & Hentze, 2004). Altering the rate of protein synthesis at the level of translation 
enables cells to respond rapidly to changes in the intra or extracellular conditions. There are 
several lines of evidence that support the involvement of translation in the regulation of cell 
proliferation and cancer development (Clemens & Bommer, 1999; Watkins & Norbury, 2002; 
Rajasekhar & Holland, 2004; Pandolfi 2004; Bilanges & Stokoe, 2007). Protein synthesis is 
coupled with cell cycle progression and is regulated in response to nutrient availability, hormones, 
mitogenic and growth factor stimulation (Caraglia et al., 2000; Meyuhas 2000; Proud 2002). 
However, the transduction pathways activated do not stimulate the translation of all the mRNAs 
equally (Holland et al., 2004). The expression of the components of the translation machinery 
might be selectively regulated by effector proteins, increasing the translation rate of specific 
oncogenic transcripts (Dua et al., 2001; Meric & Hunt, 2002; Holland et al., 2004).  
The transcriptome of a cell is a pool of mRNAs with different efficiencies. Several genes present 
typical structural features that allow a regulation of their expression at the translation level 
(Kochetov et al., 1998; Clemens & Bommer, 1999; Meyuhas, 2000). Differential recruitment of 
mRNA populations to the polisomes might be a rapid response of a cell to the signal transduction 
pathways activated, resulting in the alterations of the proteome that characterize a cancer cell 
(Clemens & Bommer, 1999; Watkins & Norbury, 2002; Rajasekhar & Holland, 2004). According 
to the ribosome filter hypothesis (Mauro & Edelman, 2002), the ribosomal subunits are also 
considered regulatory elements in translation. Specific sequences at the mRNA molecules are 
sites of interaction with either rRNAs or ribosomal proteins, especially in the 40S subunit, 
affecting translation efficiency (Tranque et al., 1998). These interactions are modulated by 
ribosomal heterogeneity, as a consequence of variation in rRNA or protein composition.  
Three main alterations at the translational level can occur in cancer cells: (i) variations in mRNA 
sequences that increase or decrease the translation efficiency of the transcript (mutations, 
alternative splicing, alternate polyadenylation sites); (ii) changes in the expression or availability 
of the components of the translation machinery and (iii) activation of translation through 
aberrantly activated signal transduction pathways.  
Translation of mRNA can be divided in three stages: initiation, elongation and termination. Each 
stage involves multiple protein factors, though the initiation step is considered the most complex 
and most tightly regulated (Gebauer & Hentze, 2004; Sonenberg & Hinnebusch, 2009). 
Therefore, it has been suggested that the initiation step represents the most suitable target for 
cancer therapy. Accordingly, several studies can be found in literature reporting that the genes 
involved in the regulation of cell proliferation, growth and death are subject to control at the 
initiation of translation level (Meric & Hunt, 2002; Stoneley & Willis, 2003; Sonenberg & Dever, 
2003; Fingar et al., 2004; Pickering & Willis, 2005; Bilanges & Stokoe, 2007). Effectively, several 
initiation and also elongation translation factors have been described to be overexpressed in 
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different human tumours (Table 2). Also, a few reports also show a down-regulation of 
translation factors expression. In addition, cancer associated point mutations were described in 
translation elongation factor genes (Frazier et al., 1998; Abbott & Proud, 2004). About 
translation termination factors, very few reports are found in literature which associate them 
with cancer development. An exception is eRF3b/GSPT2, which was reported to be over-
expressed in a study where the role of X-linked genes in breast cancer was investigated (Thakur 
et al., 2005), and was also reported as a susceptibility gene for hepatocellular carcinoma 
(Zondervan et al., 2000). 
 
Table 2: Translation factors reported to be altered in human cancers. 
Effect Type of tumor Reference
eIF2α protein Non-Hodgkin’s linfoma Wang et al. , 1999
nuclear localization Gastrointestinal carcinoma Lobo et al ., 2000
protein Melanocytic and colonic epithelial neoplasms Rosenwald et al ., 2003
eIF3a (p170) protein Lung cancer Pincheira et al. , 2001
eIF3c (p110) mRNA Testicular seminoma Rothe et al. , 2000
eIF3e (p48) LOH; protein Breast and Lung cancer Marchetti et al. , 2001
eIF3f (p47) - DNA; LOH;  mRNA & protein Pancreatic cancer Dolan et al. , 2008a
- DNA; LOH; protein Melanoma Dolan et al ., 2008b
eIF3h (p40) + DNA; mRNA Prostate and breast cancer Nupponen et al ., 1999
eIF4A1 mRNA Melanoma Eberle et al ., 1997
eIF4E protein Non-Hodgkin’s linfoma Wang et al., 1999
eIF4G  + DNA;  mRNA Squamous cell lung carcinoma Bauer et al., 2001
eEF1γ SNPs Gastrointestinal carcinoma Fraizer et al. , 1998
mRNA Oesophageal carcinoma Mimori et al. , 1996
protein Colorectal cancer Mathur et al ., 1998
mRNA Gastric carcinoma Mimori et al., 1995
eEF1A2  mRNA & protein  Ovarian cancer Anand et al., 2002
 protein Breast cancer Tomlinson et al ., 2005
 mRNA & protein  Lung adenocarcinoma Li et al., 2006
eRF3b - DNA Hepatocelular carcinoma Zondervan et al., 2000
mRNA Breast cancer Thakur et al ., 2005 
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  /: overexpression / underexpression; LOH: Loss of Heterozygosity; - /+: delection/amplification 
 
Whether if the alterations found in the components of the translation machinery are a cause or a 
consequence of malignant transformation was still a matter of debate at the time of the 
beginning of this project. However, it was already demonstrated that eIF3e (Mayeur & Hershey, 
2002), eIF4E (De Benedetti & Harris, 1999) and eEF1A2 (Wang et al., 1999), are able to 
transform cells de per se.  
 
The mammalian target of rapamycin (mTOR) pathway plays a central role in regulating protein 
synthesis, particularly cap-dependent translation. Signalling by P13K/Akt/mTOR pathway 
profoundly affects mRNA translation through phosphorylation of downstream targets. 
mTOR functions by integrating extracellular signals (such as mitogens, growth factors and 
hormones) with amino-acid availability and the intracellular energy status to control translation 
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rates (and additional metabolic processes). The mTOR promotes the phosphorylation and 
consequent activation of S6K, and the hierarchical phosphorylation of 4E-BPs. 
Hyperfosphorylated 4E-BPs are released from eIF4E resulting in enhanced cap-dependent 
translation (Mamane et al., 2006). 
Recently, Chauvin et al (2007) suggested that eRF3a also belongs to the regulatory pathway of 
mTOR activity. Although the precise role and the partners of eRF3a in mTOR signaling pathway 
were not determined, the authors suggested that eRF3a would exert a retrocontrol on the whole 
translation process, adjusting the rate of translation initiation to the efficiency of translation 
termination. 
Deregulations in mTOR signalling are frequently associated with tumorigenesis, angiogenesis, 
tumor growth and metastasis. mTOR has been extensively studied in the past years because 
rapamycin (Rapamune), a specific inhibitor of mTOR activity, shows a potent activity against a 
wide panel of cancers (Mita et al., 2003; Averous & Proud, 2006; Mamane et al., 2006).   
 
1.4.2. Trinucelotide repeats and cancer 
 
Short tandem repeats (STRs), also called microsatellites, composed of multiple di-, tri- or 
tetranucleotide repeats are widely spread in the human genome. Repetitive sequences are 
known to be hot spots for recombination as well as sites for random integration. Thus, 
alterations in simple repetitive sequences lie at the centre of DNA evolution and sequence 
diversity. On the other hand, changes in repetitive sequences can result in deleterious effects on 
gene expression and function, leading to disease. Looped DNA structures comprising 
trinucleotide repeats are frequently incorrectly processed during replication and/or repair to 
generate deletions or expansions (Di Prospero & Fischbeck, 2005; Kovtun & McMurray, 2008). 
Unstable DNA trinucleotide repeat expansion diseases represent a group of disorders that include 
mental retardation and autism, as well as several neurodegenerative and other diseases (some 
examples in Table 3).  
Expansion or contraction of STRs, due to increase or decrease in the number of repeat elements, 
gives rise to what is called microsatellite instability (MSI), often found in human cancers. The 
most common underlying cause of MSI is a defective mismatch repair (MMR) system. As a 
consequence, errors that occur during replication of DNA cannot be repaired and lead to 
nucleotide mutations and alterations in the length of repetitive microsatellite sequences. Loss of 
heterozygosity (LOH) may also occur in tumor tissues. In contrast to MSI, where new alleles are 
generated, LOH is related with the loss of a wild type allele in tumor cells. The prognostic and 
predictive value of both phenomena has been of great interest in some kinds of human tumors 
(De Schutter et al., 2007; Imai & Yamamoto, 2008). 
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Table 3: Examples of unstable triplet repeat expansion disorders. 
Triplet Gene Protein
Non-coding normal mutant
Fragil X Sindrome A CGG Fmr1 Fragile X Mental Retardation 1 5-50 200-2000
Fragil X Sindrome E GCC Fmr2 Fragile X Mental Retardation 2 6-60 >200
Friedrich ataxia GAA Fxn Frataxina 7-34 200-900
Dystrophia Myotonica 1 CTG Dmpk DM protein kinase 5-37 80-1000
Spinocerebellar ataxia 12 CTG ppp2r2b Regulatory subunit of PP2A 16-91 110-130
Huntington-like Disease (HDL-3) CTG Jph3 Junctophilin-3 8-20 >40
Coding
Poliglutamine (PoliQ)
Huntington Disease CAG It15 Huntington 11-34 36-121
Machado-Joseph Disease CAG Sca3/MJD Ataxin 3 13-40 68-69
Spinocerebellar ataxia 1 CAG Sca1 Ataxin 1 6-40 40-82
Kennedy's Disease (SBMA) CAG Ar Androgen Receptor 4-44 40-130
Dentatorubral-Pallidoluysian atrophy (DRPLA) CAG Drpla Atrophin 1 6-35 49-88
Spinocerebellar ataxia 17 CAG/CAA Tbp TATA box binding protein 25-42 43-63
Polialanine (PoliA)
Oculopharyngeal muscular dystrophy GCG Pabpn1 Poly(A)-binding protein 2 6-10 12-17
Congenital Central Hypoventilation Syndrome (CCHS) GCN Phox2b Paired-like homeobox 2B 6 9-13
Synpolydactyly GCN Hoxd13 Homeobox D13
Infantile Spasms GCC Arx Aristaless-related homeobox 10-12 17-20
Range
undetermined
 
Adapted from: Di Prospero & Fishbeck, 2005 
 
 
Microsatellites include both noncoding markers as well as repeats that are included within the 
coding regions of some genes. Some STRs may affect gene transcription, mRNA stability and 
splicing and protein structure and function. Several trinucleotide repeats have been associated 
with oncological pathologies, either conferring a protective effect or associated with elevated risk 
for disease (Table 4). The stable trinucleotide repeats (CAG)n and a (GGC)n in the androgen 
receptor (AR) gene have been extensively studied for their potential role in cancer (Ferro et al., 
2002). Although the molecular mechanisms underlying the polyglutamine and polyglycine length 
modulation of AR function have not been totally elucidated, the length of the alleles has been 
linked to prostate cancer survival and breast cancer risk (Ding et al., 2005; Schildkraut et al., 
2007; Zhang & Yu, 2007). However, results from different groups working with different racial–
ethnic populations are often inconsistent and sometimes even conflicting (Li et al., 2003; 
Schildkraut et al., 2007). 
The gene eRF3a/GSPT1 contains an exonic trinucleotide repeat in exon 1, coding for a stable 
polyglycine expansion in the N-terminal of the protein. This polymorphism in eRF3a/GSPT1 gene 
was first described in a study published in 1992 by Riggins et al., Because of a confusion 
between the names of the genes, the authors designed primers specific for eRF3a/GSPT1 gene, 
which was formerly designated by GST1 (as mentioned in section 1.1.), but reported in the 
paper that the gene studied was the gene encoding Glutathione-S-transferase-1 (GST1). 
Nevertheless, using those primers, they identified 5 different alleles that enclosed 8, 10, 11, 12 
and 13 GGC repeats in the 5’UTR of the gene. A few years later, Prof Carolino Monteiro 
(Faculdade de Farmácia da Universidade de Lisboa) was engaged in a project about the 
association between p53 genomic instability with Glutathione-S-transferase-1 and decided to use 
the primers from the paper cited above to analyse the reported polymorphism. He found 
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interesting preliminary results: the frequencies of the alleles were significantly different between 
gastric cancer patients and control healthy individuals, being some of the alleles detected 
exclusively in the cancer patients (Carolino Monteiro, personal communication). Thus, he decided 
to sequence the fragments amplified, and realized that the region amplified was located in exon 
1 of eRF3a/GSPT1 gene and not in the GST1 gene encoding Glutathione-S-transferase-1, as 
mentioned in the original paper.  
 
Table 4: Genes with STR polymorphisms associated with cancer. 
Gene Protein Repeat Position Disease Reference 
Aib1 Nuclear receptor coactivator 3 CAG Exon 1 Prostate cancer Hsing et al. , 2002
Breast cancer Dai & Wong, 2003
Ar Androgen receptor CAG, GGC Exon 1 Prostate cancer Chang et al. , 2002
Breast cancer Suter et al ., 2003
Urothelial carcinoma Liu et al ., 2008
Cyp11a Cytochrome P450, family 11 TAAAA Promotor Prostate cancer Kumazawa et al ., 2004
Breast cancer Zheng et al ., 2004
Cyp19 Cytochrome P450, family 19 TTTA Intron 4 Breast cancer Haiman et al ., 2000
Prostate cancer Suzuki et al. , 2003
Ecrg2 (esophageal cancer-related protein 2) TCA Exon 4 Esophageal cancer Kaifi et al ., 2007a
Pancreatic carcinoma Kaifi et al ., 2007b
Er Estrogen receptor GT Promotor Breast cancer Cai et al. , 2003
Erbb-1 Epidermal growth factor receptor CA Intron 1 Breast cancer Tidow et al ., 2003
Lung cancer Nie et al. , 2007
E2f-4 E2F transcription factor 4 AGC Exon 7 Colorectal cancer Zhong et al. , 2000
Breast cancer Ho et al ., 2001
Ho-1 Heme Oxygenase-1 GT Promotor Chronic Pulmunary Emphysema Yamada et al ., 2000
Melanoma Okamoto et al. , 2006
Male oral squamous cell carcinoma Vashist et al. , 2008
Infg Interferon, gamma CA Intron 1 Breast cancer Saha et al ., 2005
IGF-1 Insulin-like growth factor 1 CA Promotor Prostate cancer Friedrichsen et al ., 2005
Breast cancer Cleveland et al ., 2006
Colorectal cancer Zecevic et al. , 2006
Smyd3 SET and MYND domain containing 3 CCGCC Promotor Colorectal Cancer Uthoff et al ., 2002
Tcr-gamma T-cell receptor-gamma GATA Intronic Non small cell lung cancer Tseng et al ., 2005
Different types of cancer Tsuge et al. , 2005
Hepatocellular carcinoma Hsu et al ., 2006  
 
 
 
1.5. Aims and thesis structure 
 
In spite of the extensive data available about the involvement of translation (de)regulation in 
association with cancer development, the contribution of the eukaryotic translation release 
factors remained to be evaluated. Being the eRF3a involved in several essential pathways in the 
cell, it was an appealing idea to evaluate it’s involvement in the carcinogenesis process. 
 
To accomplish this purpose, six specific aims were established as the basis for this thesis: 
 
1) To quantify eRF3a/GSPT1 gene expression at the mRNA and protein level in different types of 
human cancers, and correlate the level of expression with the length of the STR alleles. 
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2) To determine the genotype of the STR polymorphism in eRF3a/GSPT1 exon 1 in patients with 
different kinds of human tumors, and compare the allele frequencies with a control healthy 
population.  
  
3) To analyse and compare the efficiency of eRF3a proteins encoded by alleles with different 
number GGC repeats, as translation termination factors.  
 
4) To analyse and compare the viability and apoptosis rates of cells expressing the eRF3a protein 
variants with different N-terminal lenghts.  
 
5) To analyse and compare the efficiency of the eRF3a protein variants in cytoskeleton 
organization. 
 
6) Integrate the above results and discuss how eRF3a/GSPT1 can be involved in malignant 
transformation. 
 
To address the specified aims, the dissertation is organized in five chapters. Chapter I 
corresponds to the general introduction of this dissertation. Chapters II and III are composed of 
a total of 5 papers, already published (4) or submitted for publication (1) in international 
scientific journals: Papers 1 and 2 in Chapter II and Papers 3, 4 and 5 in Chapter III. Chapter IV 
comprises an integrative discussion of the results obtained and published in the papers 
presented. Finally, Chapter V contains the final remarks of the thesis. 
The first aim is addressed in papers 1, 3 and 4. In Paper 1 we quantified the mRNA levels of 
expression of eRF3a/GSPT1 gene in gastric cancer patients, and correlated the pattern of 
expression with gene dosage in each sample. Paper 3 analyses the expression of eRF3a/GSPT1 in 
breast tumors and reinforces that the expression of this gene is deregulated in cancer cells; this 
paper also suggests that the levels of expression of eRF3a/GSPT1 are correlated with the size of 
the (GGC)n microsatellite alleles. This suggestion if confirmed in Paper 4 using primary 
lymphocyte cultures with different genotypes and Jurkat-modified cell lines expressing different 
alleles. In this paper, the methylation levels of the CpG sites within the GGC expansion were 
quantified in each allele and correlated with the mRNA levels. 
Our second aim is addressed in papers 2, 3 and 4. In Paper 2 we determined the genotypes of 
the STR polymorphism of eRF3a/GSPT1 in gastric cancer patients and screened for additional 
genetic variability in linkage with the alleles detected. We also estimated the relative risk of 
cancer development associated with each allele and genotype. In Paper 3, we analyzed the 
frequencies of the alleles and genotypes in the breast cancer patients, and the same analysis 
was performed in Paper 4 for patients with colorectal cancer and Crohn Disease.    
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The third aim is addressed in Paper 3, using a cell line stably expressing β-galactosidase gene 
with a premature stop codon. The efficiency of eRF3a variants as translation termination factors 
was evaluated by quantifying the level of readthrough in the reporter gene. 
The fourth aim is addressed in Paper 4 using cytometry to measure and compare several 
parameters of cell cycle and apoptosis between primary lymphocyte cultures with different 
genotypes and between Jurkat-modified cell lines expressing different alleles. 
The fifth aim is addressed in Papers 4 and 5. In Paper 4 we used a cytokinesis-block 
micronucleus assay to quantify the frequency of micronucleus in the same cell lines, as a marker 
of chromosomal damage caused by defects in mitotic spindle formation. In Paper 5 we 
investigated the existence of correlations between the expression of eRF3a/GSPT1 and the 
pattern of expression of several genes encoding proteins that belong to tubulin folding pathway, 
that ultimately regulate the formation of microtubules that compose the cytoskeleton.  
The fifth and last aim of this thesis is partly addressed in all the papers that compose Chapters II 
and III, but is fully explored in Chapter IV, in which all the results are integrated and examined 
in detail to evaluate the contribution of eRF3a/GSPT1 (de)regulation to the carcinogenesis 
process.  
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ABSTRACT 
 
The human eukaryotic release factor 3a (eRF3a), encoded by eRF3a/GSPT1 gene, is up-
regulated in various human cancers. eRF3a/GSPT1 contains a (GGC)n polymorphism in exon 1, 
encoding a polyglycine expansion in the N-terminal of the protein. The longer allele (12-GGC) 
was previously shown to be associated to cancer. Here we show that the 12-GGC allele is 
present in colorectal cancer patients (allele frequency = 1.09%) but not in Crohn Disease 
patients and the control population. Using real time quantitative RT-PCR we show that the 12-
GGC allele present up to 10-fold higher transcription levels than the 10-GGC allele (p<0.001). 
No eRF3a/GSPT1 amplifications were detected and there was no correlation between the 
length of the alleles and methylation levels of the CpG sites inside the GGC expansion.  
Using flow cytometry, we compared the levels of apoptosis and proliferation rates between cell 
lines with different genotypes, but no significant differences were detected. Finally, we used a 
cytokinesis-block micronucleus assay to evaluate the frequency of micronucleus in the same 
cell lines. Our results show that cell lines with the longer alleles have higher frequencies of 
micronucleus in binucleated cells, which is probably a result of defects in mitotic spindle 
formation. Taken together, our results show that eRF3a should be considered as a potential 
proto-oncogene. 
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INTRODUCTION 
 
In humans, the eukaryotic release factor 3 (eRF3) has two distinct isoforms: eRF3a, encoded by 
eRF3a/GSPT1 gene located in 16p13.1 [1] and eRF3b, encoded by eRF3b/GSPT2 gene located in 
Xp11.21-23 [2]. eRF3a/GSPT1 mRNA is abundant in all tissues and its level varies during the cell cycle, 
whereas eRF3b/GSPT2 mRNA is poorly expressed in most mouse tissues tested, except in brain [3]. It 
was previously reported that eRF3a/GSPT1 mRNA level is increased in intestinal type gastric tumors and 
breast cancer [4,5] and strongly decreased during human chondrocytes differentiation [6].  
Eukaryotic translation termination is governed by two release factors, eRF1 and eRF3. These factors 
associate in a complex which binds to the ribosomal A site. eRF1 recognises the three stop codons, and 
promotes the hydrolysis of the peptidyl-tRNA and the release of the nascent polypeptide chain. eRF3 is a 
small GTPase that enhances eRF1 activity [7]. eRF3a and eRF3b proteins share 87% identity, most of 
the differences being concentrated in their N-terminal domains. The C-terminal region of eRF3 proteins is 
highly conserved and essential for translation termination and interaction with eRF1 whereas the N-
terminal region varies in length and sequence among species [7]. It was recently shown that this domain 
also influences eRF3 functions in translation and possibly in other cellular processes [8,9]. Beside eRF3 
roles in translation termination and related pathways, this factor was also reported to be involved in cell 
cycle progression [3,10], apoptosis regulation [11] and cytoskeleton organization [12-14]. 
The N-terminal domain of human eRF3a contains a polyglycine expansion encoded by a stable (GGC)n 
polymorphism in eRF3a/GSPT1 first exon. As it is implicated in essential cellular processes, modifications 
in the amino-terminal domain of eRF3a might be of crucial relevance. We recently reported a strong 
association between the longest allele (12-GGC) and cancer development [5,15], which was shown to be 
a germline mutation.  
In this study we aimed to gain new insights into the role of the (GGC)n expansion in eRF3a/GSPT1 gene 
expression regulation, and ultimately to evaluate eRF3a/GSPT1 as a biomarker for cancer diagnosis. 
Screening for the 12GGC allele in eRF3a/GSPT1 exon 1 might provide a molecular tool able to identify 
individuals at risk, as well as possible targets for therapy. Furthermore, a better understanding of 
eRF3a/GSPT1 gene expression regulation can shed light on understanding the origin and progression of 
tumors in general.  
Colorectal cancer (CRC) is one of the most prevalent cancers and leading cause of cancer mortality 
worldwide. Five to ten percent of all cases are due to highly penetrant mutations in single genes, giving 
rise to hereditary syndromes that are mostly transmitted as autosomal dominant traits. Low penetrance 
susceptibility genes account for a high proportion of colorectal cancer in both familial and sporadic CRC 
[16]. Crohn’s disease (CD) is a chronic inflammatory disease that can affect the entire gastrointestinal 
tract from the mouth to the anus. Inflammation has long been associated with the development of cancer. 
Nowadays, the association between CD and increased risk for CRC is widely accepted [17]. CRC is the 
most common type of cancer in inflammatory bowel disease (IBD), although cancer in other organs can 
occur. Although CRC associated to IBD accounts only for 1%-2% of all cases of CRC in the general 
population, it is considered a serious complication of these diseases and accounts for approximately 
10%-15% of all deaths in IBD patients [18]. Several of the molecular alterations that contribute to sporadic 
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CRC are also found in IBD-associated CRC [17]. CD is a complex disease in which multiple genetic and 
environmental factors are likely to contribute to pathogenesis, and the search for CD susceptibility genes 
therefore poses similar problems to those in other complex disorders.  
In this study, we detected the 12-GGC allele in 2,2% of the CRC patients, but not in the CD and control 
populations.  Also, we confirmed that the 12-GGC allele of eRF3a/GSPT1 mRNA levels are significantly 
up-regulated, when compared with the shorter (GGC)n alleles, both in primary lymphocyte cultures and in 
Jurkat modified cell lines. To explore which mechanisms might be responsible for 12-GGC up-regulation, 
we analysed and correlated eRF3a/GSPT1 expression with CpG methylation within the GGC expansion 
and eRF3a/GSPT1 gene copy number. Further, we have determined and compared proliferation and 
apoptosis rates in cells expressing eRF3a proteins with 7-12 Gly residues. Finally, we evaluated the 
impact of the length of the N-terminal domain of eRF3a in ensuring a correct mitotic spindle assembling. 
Our data show that there are similar overall efficiencies in what concerns eRF3a role in apoptosis, and we 
did not detect quantitative differences on the cell cycle progression parameters between all the (GGC)n 
alleles tested.  However, the longer alleles seem to differentially ensure the genome stability, as revealed 
by the occurrence of greater number of micronucleus in cells expressing eRF3a/GSPT1 12-GGC allele. 
Our data suggest that specific gene expression profiles that distinguish eF3a/GSPT1 alleles may 
contribute to their different roles in the tumorigenesis process. 
 
 
MATERIALS AND METHODS  
 
Study subjects  
Study subjects were patients from Instituto Português de Oncologia – Lisboa, and were included in the 
study after informed consent was obtained. This study was approved by the Scientific and the Ethical 
Committees. Our samples included 138 individuals with colo-rectal cancer (CRC) and 94 individuals with 
Crohn Disease (CD). The tumors were diagnosed as CRC after histopathological examination performed 
in the department of pathology. The control population was composed of 135 healthy blood donors, 
adjusted for age and sex. 
 
DNA isolation  
DNA from CRC patients was isolated from blood spots using The Generation Capture Card Kit (Gentra 
Systems, Minneapolis, USA), according to the manufacturer instructions. DNA from controls and CD 
patients was extracted from peripheral blood using a standard phenol-chloroform extraction [19].  
 
Patients genotyping for the STR alleles 
The (GGC)n fragment in eRF3a/GSPT1 was PCR amplified using a 6’-FAM labelled forward primer (5’-
CATTTCTCGCTCTCTGTCCAC-3’) and a non-labelled reverse primer (5’-CTGGTCCCAGCAGTCAGG-
3’) as described previously [4], being genotyped in an ABI 310 sequencer and analysed with GeneScan 
3.7 software (Applied Biosystems, Foster City, California, USA). Direct DNA sequencing of each detected 
allele was performed to confirm the GGC repeat length.  
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Quantitative Methylation analysis  
After bisulphite conversion of genomic DNA, the target region including the GGC expansion was PCR 
amplified. PCR reactions included 1x buffer USB containing 1.5 mmol Mg2+, 0.5 mM MgCl2, 0.35 mM  
dNTP, 0.22 µM Forward primer, 0.22 µM 5’-biotinylated Reverse primer and 0.04U USB HotStartTaq IT 
DNA polymerase (USB Corporation, Cleaveland USA), in a total of 45 volume reaction. Cycling conditions 
were as follows: 94°C 3’, 50x (94°C 35’’, 63.6°C 35’’, 72°C 35’’), 72°C 5’. For heterozygous samples, an 
extra PCR reaction was performed (reverse assay) in order to analyse both alleles independently. 
Reaction conditions were the same as described above. Primers are listed in Table 1. 
 
Table 1: Primer’s sequences for pyrosequencing assays 
 
Sample preparation was carried out using Vacuum Prep Tool according to standard procedures. 40-45µl 
PCR product was immobilized to 3µl Streptavidin Sepharose™ HP beads (GE Healthcare, Germany) 
followed by annealing to 0.2µM sequencing primer for 2’ at 80°C. Pyrosequencing reaction is performed 
using the PSQ ID System (Biotage, Uppsala, Sweeden) by the sequential addition of single nucleotides in 
a predefined order. CpG analyses were done with Pyro Q-CpG software (Biotage). 
 
Primary lymphocyte cultures 
Thirty patients were selected according to their genotypes, and 10ml of peripheral blood were drawn into 
tubes containing heparine (Sigma, St. Louis, USA) as anticoagulant. Lymphocytes were isolated by 
density centrifugation (Ficoll-Paque; GE Healtcare) and cultured in a humidified 5% CO2 incubator at 
37°C in RPMI 1640 medium (Sigma) supplemented with 10% fetal bovine serum (Sigma), antibiotics (100 
U/ml penicillin and 50µg /ml streptomycin) and 10µg/ml phytohemagglutinin (Sigma). Lymphocytes (105 
cells/well) were incubated in six-well tissue culture plates in 5 ml medium. 
 
eRF3a modified cell lines  
The human eRF3a/GSPT1 cDNA containing 10 GGC repeats was cloned into the pBK-CMV expression 
vector (Stratagene, La Jolla, USA), as described previously [20]. 
This original plasmid pCMV-heRF3a was used to construct other plasmids expressing eRF3a with 
different GGC repeat length alleles. eRF3a/GSPT1 exon 1 fragments with GGC repeat length of 7, 9, 10, 
11, and 12 were amplified by PCR from genomic DNA of previously genotyped patients, using 
5’CCATTTCTCGCTCTCTGTCCACC3’ and 5’ACTCAACGTCAACGCCAAG3’ primers. The PCR 
fragments were digested with XmaI and BamHI, purified, and ligated into the XmaI/ BamHI fragment of 
pCMV-heRF3a, as described previously [5]. The five eRF3a-(GGC)n expression plasmids obtained were 
sequenced to verify the correct sequence and GGC repeat length of the inserts. 
  Forward Assay Reverse Assay 
Forward atggtttttttgattatggatttgggtagtgg gggattggagttgttgttgtggtgatg 
Reverse Biotin-cccaacccaaaaacttccatatccacctaa Biotin-aaaaacccaacccaaaaacttccatatccacctaat 
Sequencing ttttttgattatggatttg actactactaccactactactcc 
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Jurkat cells (ATCC Cat. No. TIB-152) were maintained in RPMI medium (Sigma) supplemented with 10% 
fetal bovine serum and antibiotics (100 U/ml penicillin and 50µg /ml streptomycin). 2x105 cells were 
transfected with 1 µg of each eRF3a-(GGC)n plasmid using Lipofectamine™ LTX Reagent (Invitrogen, 
Carlsbag, CA, USA) added by Plus Reagent (Invitrogen), according to the manufacturer’s protocol. Five 
distinct Jurkat-eRF3a(GGC)n cell lines were obtained, each expressing an eRF3a protein with different N-
terminal domain length. 
 
eRF3a/GSPT1 gene expression 
48h after the establishment of lymphocyte primary cultures, 105 cells were collected and washed with ice-
cold PBS 1X (Sigma). In what concerns the Jurkat-(GGC)n cell lines, 48h after transfections, 105 cells 
were harvested for analysis of RNA levels. 
Total RNA was extracted using the SV Total RNA Isolation System (Promega, Mannheim, Germany), as 
recommended by the manufacturer. First strand cDNA was synthesised using MultiScribeTM reverse 
transcriptase (Applied BioSystems), with random hexamers, according to the manufacturer’s instructions 
in a total volume of 50 µl; samples were incubated at 25˚C 10’, 48˚C 30’, 95˚C 5’. 
Relative expression of eRF3a/GSPT1 was investigated using real time quantitative RT-PCR using gene-
specific primers and TaqMan probes, as described in Malta-Vacas et al. [15]. Relative quantification of 
the mRNA levels of eRF3a/GSPT1 was determined using the ∆∆CT method [21]. Briefly, the amount of 
target was normalised to the endogenous reference gene (18S rRNA PDAR, Applied BioSystems) and its 
expression was calculated relative to a calibrator sample. Final results are expressed as N-fold difference 
in target sample expression relative to a calibrator sample. 
 
eRF3a/GSPT1 genomic DNA quantification 
Genomic DNA was isolated from the remaining pellet of lysed cells used for RNA extraction, following a 
standard protocol of phenol-chlorophorm extraction. 
Gene dosage was assessed by quantitative real time PCR using SYBR Green dye I as the fluorescent 
signal. This assay relies on a comparison of the amount of product generated from the target gene 
(eRF3/GSPT1) and that generated from a disomic reference gene (β-actin). Equal PCR efficiencies for 
both genes have been validated previously [15]. A fragment of genomic DNA from eRF3/GSPT1 was 
amplified using SYBR Green PCR Master Mix (Applied BioSystems) in a 20 µl reaction volume and the 
endogenous control gene β-actin was measured simultaneously. Each series of PCR reactions included 
triplicates for all tumor and normal samples, a non-template control, and a five point standard curve, 
established using serial dilutions (1/2, 1/5, 1/10, 1/100 and 1/500) of a known disomic sample for both 
genes. PCR reactions were performed in the iCycler iQ Real-Time PCR Detection System (BioRad, 
Hercules, California, USA). Cycling conditions were: 50˚C 2’, 95˚C 10’, 40x (95˚C 15’’, 60˚C 1’). In each 
experiment the threshold cycle was manually adjusted and Ct values were averaged for each sample. A 
standard curve was established for each gene using the serial dilutions. For each sample, the amount of 
eRF3/GSPT1 and β-actin was determined from the standard curve. The gene dosage of eRF3/GSPT1 
was calculated by the ratio of its amount and the amount of the reference gene. The ratio of tumor to 
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normal is expected to be 1 for disomic samples, greater than 1 if there are allele amplifications, and less 
than 1 in the presence of allele deletions. 
After the amplification reaction, melting curves were constructed from 45°C–95°C to confirm the 
specificity of the PCR products.  
 
Analysis of apoptosis and proliferation rates 
Apoptosis was evaluated using the Annexin V-FITC Apoptosis Detection kit (BD Biosciences, San Jose, 
CA, USA) according to the manufacturer's instructions. The test is based on the selective affinity of 
annexin V for phospholipid phosphatidylserine, which is translocated from the inner to the outer layer of 
the cell membrane of apoptotic cells [22]. Both primary lymphocyte cultures and Jurkat-eRF3a(GGC)n 
cell line were tested.  
After 72h in culture, 106 cells were harvested, washed twice with PBS and stained with annexin V-FITC 
and propidium iodide (PI) for 15 min at room temperature. Stained cells acquisition was performed by 
quadrant dot plot dual parameter analysis on a FACScan flow cytometer (Becton Dickinson, Mountain 
View, CA), equipped with a laser emitting excitation light at 488 nm. Fluorescence compensation was 
adjusted to minimize overlap of FL1 and FL2 signals. Annexin V-/ PI- cells were considered as viable 
cells; annexin V+/ PI- cells as in early apoptosis, whereas annexin V+/ PI+ cells are necrotic or in late 
apoptosis. "Starving cells" that easily undergo apoptosis were used as positive staining control. Data 
were analysed using the PAINT-A-GATE software (BD Immunocytometry Systems, San Jose, CA), and 
expressed as percentage of the total cells evaluated.  
Cell proliferation studies were performed on 106 frozen cells using DNA flow cytometry analysis according 
to the method of Deitch et al. [23]. After washing twice, the cells nuclei were stained with PI (Sigma) in 
Tris-MgCl2 buffer, treated with Ribonuclease (Sigma) and non-ionic detergent Nonidet P40 (Sigma) for 1 
hour in the dark at 4ºC, and further acquired on a FACScan instrument (BD Biosciences). Cell cycle 
analysis of DNA histograms was performed using the ModFit LT software (Verity Software House, Inc., 
Topsham, ME). As measures of cell proliferation, the S-phase fraction and the Proliferative Index 
(S+G2M) were determined from the histogram as the percentage of cells in the respective phase of the 
cycle. 
 
Cytokinesis-block Micronucleus assay 
The Cytokinesis-block Micronucleus assay (CBMN) was performed in Jurkat-(GGC)n cell lines and in 
patient’s lymphocyte primary cultures.  6µg/ml cytochalasin B (Sigma) were added to the culture medium 
44 h after transfections or cultures establishment, to Jurkat-(GGC)n cells or lymphocyte cultures, 
respectively. 28h later, the cells were harvested, and 100µl of the cell suspension were spun onto 
microscope slides using a cytocentrifuge (Shandon, Pittsburgh, PA, USA). The slides were dried and 
double stained May-Grünwald-Giemsa (Sigma) and mounted with Entellan (Merck, Darmstadt, Germany). 
For each sample, 1000 binucleated cells were scored blindly using a ZEISS light optical microscope 
following the scoring criteria outlined by HUMN Project [24]. Monitored values included: number of mono-, 
bi-, and multinucleated cells, incidence of micronuclei, nucleoplasmic bridges, and nuclear buds and 
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cytokinesis block proliferation index (CBPI). Micronucleus incidence was presented as the number of 
micronuclei per 1000 examined binuclear cells. 
CBPI was calculated according to formula: CBPI = (M1 + 2M2 + 3(M3+M4)) / N, where M1-M4 represents 
the number of cells with 1 to 4 nuclei found, respectively, and N is the total number of scored cells. The 
CBPI is a measure of the average number of cell cycles that a cell population passes through, 
considering both three-nucleated and tetra-nucleated cells in the same category. 
 
Statistical analysis 
Allele frequencies and Fisher’s tests were calculated in GENEPOP, version 1.2 [25]. Case-control odds 
ratios (OR) and 95% CI (confidence intervals) were calculated as estimators of relative risk, according to 
Sokal & Rohlf [26]. Non-parametric correlations were evaluated by Spearman’s correlations, one-way 
analysis of variance (ANOVA) was used for comparisons between groups and T-Test between pairs of 
groups, using SPSS 15.0 statistical package (SSPS Inc., Chicago, IL, USA). A p value <0.05 was defined 
as significant.  
 
 
RESULTS 
 
GGC expansion polymorphism of eRF3a/GSPT1  
The genotypes of 138 colorectal cancer (CRC) patients, 94 Crohn Disease (CD) patients and 135 healthy 
blood donors were determined by fluorescent PCR amplification and peak detection in an automatic 
sequencer. 
The five known eRF3a/GSPT1 GGC alleles corresponding to 7, 9, 10, 11 and 12 GGC repeat units were 
identified. The 10-GGC allele was the most frequent in the three samples. The 9-GGC allele was 
exclusively detected in the control population, while the 12-GGC allele was only detected in CRC patients, 
as shown in Table 2.  
Using the Fisher’s test method, we detected significant differences between the CRC and CD populations 
both in allelic (χ2= 6.513; p=0.03852) and genotypic (χ2= 7.105; p=0.02866) frequencies. 
To measure the association of the alleles of eRF3a/GSPT1 gene with disease development, case-control 
odds ratios (OR) and 95% CI (confidence intervals) were calculated as estimators of relative risk. The 
analysis did not reveal any statistically significant risk or protective effect associated to any particular 
allele/genotype, except for the 10-11GGC genotype which is marginally significantly protector in CD 
(Table 2). Although not statistically significant, the 12-GGC allele is associated with a 6-fold increased risk 
for CRC and the 9-GGC allele presents a 5-fold protective effect for both diseases.  
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Table 2: Allelic and Genotypic Frequencies and Odds Ratio analysis 
 
 CRC   CD  
 F (%)  OR   CI   F (%)   OR   CI  
Alleles             
7  5.43   0.67   0.35 - 1.36   11.7   1.5   0.80 - 2.82  
9  -   0.19   0.01 - 3.98   -   0.29   0.01 - 6.02  
10  70.65   Ref     68.62   Ref  
11  22.83   0.96   0.64 - 1.44   19.68   0.86   0.54 - 1.37  
12  1.09   6.64   0.34 - 129.47   -   1.43   0.03 - 72.66  
 Genotypes              
 7-7   -   0.27   0.01 - 6.76   1.06   1.22   0.12 - 12.13  
 7-10   9.42   0.99   0.44 - 2.21   15.96   1.15   0.52 - 2.54  
 7-11   1.45   0.58   0.11 - 3.05   5.32   1.92   0.47 - 7.75  
 9-10   -   0.16   0.01 - 3.45   -   0.24   0.01 - 5.21  
 10-10   49.28   Ref     47.87   Ref  
 10-11   32.61   0.64   0.38 - 1.09   25.53   0.52   0.28 - 0.96  
 10-12   0.72   2.43   0.10 - 60.85   -   1.22   0.02 - 62.70  
 11-11   5.07   4.05   0.67 - 24.23   4.26   3.66   0.55 - 24.20  
 11-12   1.45   4.05   0.19 - 86.14   -   1.22   0.02 - 62.70  
(CRC: colorectal cancer; CD; Crohn’s Disease; F: frequency; OR: odds ratio; CI: confidence interval) 
 
Correlation between GGC repeat number and methylation levels   
The number of GGC repeats in eRF3a/GSPT1 exon 1 is directly proportional to the number of CpG sites 
inside the expansion. Because epigenetic changes may contribute to gene expression alterations, we 
used pyrosequencing technology to perform a quantitative analysis of the methylation status of the CpG 
sites located within the GGC repeat expansion. 
Twenty five DNA samples were analysed, comprising all the genotypes detected and including DNA 
isolated from tumor tissue samples, normal tissue adjacent to the tumor, blood samples from cancer 
patients and blood from control individuals. All CpG sites in every sample showed no methylation. Figure 
1 represents a representative pyrogram quantifying methylation levels at CpG sites within the GGC 
expansion in the first exon of eRF3a/GSPT1 gene. The GGC repeat length variation from 7 to 12 appears 
to have no effect on the methylation status of the region, regardless of the source of the DNA sample. 
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Figure 1: Representative pyrogram quantifying methylation levels at 12 CpG sites in a 146bp PCR 
fragment containing 12GGC repeats. The order of nucleotide dispensation (sequence below chart) is 
chosen by the software on the basis of the sequence context. E and S indicate Enzyme and Substrate 
control in the reaction, respectively. Values between 1-4% are within the sensitivity and error range of 
pyrosequencing, 
 
eRF3a/GSPT1 mRNA expression in primary lymphocytes cell lines 
In order to evaluate if the length of the GGC repeat expansion could in some way modulate 
eRF3a/GSPT1 gene transcription, we obtained primary cultures of lymphocytes isolated from selected 
individuals. Thirty two primary cell lines were established, including six different genotypes (7-10GGC, 7-
11GGC, 10-10GGC, 10-11GGC, 11-11GGC and 11-12GGC). 
After 48h in culture, cells were collected and the levels of expression of eRF3a/GSTP1 were determined 
by a quantitative real time PCR. As shown in Figure 2A, the mRNA levels of eRF3a/GSPT1 show 
significant variation between the genotypes, as revealed by the one-way variance test ANOVA (p=0,001). 
When compared to the levels of expression in the 10-10GGC genotype (considered as reference), the 
cells representing the genotype 11-12GGC present a 7,6-fold increased in the mRNA level. 
 In order to evaluate if the DNA copy number alterations could be responsible for variations in the levels 
of expression of eRF3a/GSPT1 gene, we used a real-time PCR assay to measure the gene dosage of 
eRF3a/GSPT1 relative to a disomic gene (β-actin) in the same primary cell lines.  
Gene dosage of eRF3a/GSPT1 show no variation between the genotypes (see Fig. 2B), as revealed by 
the one-way variance test ANOVA (p=0.97). The eRF3a/GSPT1 copy number assessment showed that 
only 1 out of 30 cell lines presented genetic losses (eRF3a/GSPT1 / β-actin = 0.29). However, the levels 
of mRNA expression in this 10-10GGC cell line are within the same range as the other cell lines with the 
same genotype. For all the remaining cell lines, quantitative results ranged from 0.65 to 1.28, which is in 
the range of expected values for disomic samples. We did not detect eRF3a/GSPT1 amplifications in any 
of the cell lines analysed. 
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Figure 2: Quantitative analysis of eRF3a/GSPT1 mRNA and DNA levels in primary lymphocyte cell lines 
derived from patients with different genotypes. A) mRNA levels were quantified by reverse-transcription 
real time PCR using gene specific primers and TaqMan Probes. 18SrRNA was used as endogenous 
control gene. The cell lines with the 10-10GGC genotype were considered as reference. The level of 
eRF3a/GSPT1 is standardized to 1 for the reference genotype. The levels of expression of 
eRF3a/GSPT1 in the other cell lines (with different genotypes) are expressed as n-fold difference, when 
compared to the reference. Error bars represent the standard error of the mean. T-Test were used to 
evaluate differences between each group and the reference:**p<0.005 
B) DNA levels were quantified by a SYBR Green based real time PCR assay using β-actin as reference 
disomic gene. Gene dosage is expressed as the ratio between eRF3a/GSPT1 and β-actin. Error bars 
represent the standard error of the mean.  
 
Translation termination factor’s mRNA expression in immortalized lymphoblastoid cell lines  
We quantified eRF3a/GSPT1 mRNA levels of expression in Jurkat-eRF3a(GGC)n cell lines, derived from 
the Jurkat lymphoblastoid cell line, that transiently express eRF3a/GSPT1 alleles encoding proteins with 
different glycine expansion lengths. 
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As can be observed in Figure 3A, the mRNA levels of eRF3a/GSPT1 show significant variation between 
the genotypes (p<0.0001). The Jurkat-9GGC cell line mRNA level was 17-fold lower and the Jurkat-
12GGC mRNA level was 12-fold higher, when compared with the reference Jurkat-10GGC cell line. 
We also quantified eRF3b/GSPT2 mRNA levels to determine whether the changes in eRF3a/GSPT1 
levels were adjusted by modifications in eRF3b/GSPT2 gene expression. Significant differences between 
genotypes were also detected (p<0.05), as shown in Fig 3B. However, when the level of eRF3b/GSPT2 
mRNA in each cell line was compared with the level of expression in the reference cell line, only the 
Jurkat-7GGC level of eRF3b/GSPT2 was significantly different (6-fold lower than in the Jurkat-10GGC 
cell line). 
In what concerns eRF1, the key factor in translation termination, there were no variations in the mRNA 
levels between cell lines with different genotypes (p>0.05), as shown in Fig 3C. 
 
Analysis of apoptosis and proliferation rates 
To evaluate whether the length of the GGC repeat expansion in the first exon of eRF3a/GSPT1 gene 
might be related to the protein role as an inhibitor of apoptosis binding protein (IAP-BP) we quantified the 
levels of apoptosis in cells expressing proteins with 7-12 Gly residues in the N-terminal of eRF3a.  
 We first compared the lymphocyte primary cell lines and, as can be appreciated in Figure 4A, there were 
no significant statistical differences between different genotypes in what concerns the number of viable 
cells, number of death cells and total apoptotic cells. Interestingly, there was a positive correlation 
between the number of viable cells and increased number of GGC repeats (r=0.370, p=0.048) as well as 
a negative correlation between the number of apoptotic cells and the GGC repeat number increase 
(r=−0.411, p=0.027). In what concerns the same analysis in Jurkat-eRF3a(GGC)n cell lines (Figure 4B), 
no statistically significant difference was observed between cell lines with different genotypes in the 
parameters analysed, and the correlations could not be confirmed. 
We also analysed the cell cycle status in the same cell lines. With regard to the percentage of cells in S-
phase and the proliferation index (S+G2M), no statistically significant difference was found between cell 
lines with different genotypes (Figure 4C and 4D). Moreover, any correlation between these cell cycle 
parameters and the number of GGC repeats could be established.   
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Figure 3: Relative gene expression levels in Jurkat-eRF3a(GGC)n cell lines. mRNA levels of 
eRF3a/GSPT1 (A), eRF3b/GSPT2 (B) and eRF1 (C) were quantified by reverse-transcription real time 
PCR. The cell line transfected with the 10GGC allele was considered as reference. The level of mRNA of 
the target gene is standardized to 1 in the reference cell line. The levels of expression of the target genes 
in the other cell lines are expressed as n-fold difference, when compared to the reference. Results 
presented are the mean of 3 experiences. Error bars represent the standard error of the mean. T-Test 
were used to evaluate differences between each cell line and the reference:*p<0.05. NT: Non-transfected 
cell line; P: cell line transfected with an empty vector. 
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Figure 4: Flow cytometric analysis of apoptotic and proliferation parameters in cells expressing proteins 
with 7-12 Gly in the N-terminal of eRF3a. Percentage of viable cells, dead cells and total apoptotic cells 
were determined for lymphocyte primary cultures of patients with different genotypes (A) and in Jurkat-
(GGC)n cell lines (B). The percentage of cells in S-Phase and the Proliferation Index S+G2M were 
calculated for the same lymphocyte primary cultures (C) and for Jurkat-(GGC)n cell lines (D). 
 
 
Cytokinesis-block micronucleus assay 
The cytokinesis-block MN (CBMN) assay was performed in Jurkat-(GGC)n cell lines and patient’s 
lymphocyte primary cultures, analyzing a minimum of 1000 binucleated cells per each cell line. The 
CBMN assay showed that formation of micronucleus is more frequent in cell lines with longer GGC 
expansions (Table 3). The cell line Jurkat-12GGC showed the highest number of MN frequencies in 
binucleated cells (20.87). This cell line also presented the highest number of Tri- and Tetranucleated cells. 
In what concerns the lymphocyte cultures, the same pattern was observed: the cells with the 12-GGC 
allele showed the highest incidence of MN in bi-nucleated cells (21.98), being the increase roughly of the 
same order of magnitude when compared to the reference 10-10GGC genotype (3.33 MN / 1000 
binucleated cells). 
Regarding cytokinesis block proliferation index (CBPI) values, the results showed that the variation in the 
GGC expansion length did not affect this proliferation index.  
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Table 3: Cytogenetic analysis of cytokinesis-blocked cultured (Jurkat-GGC)n cells. Frequencies of all 
parameters are calculated relative to 1000 binucleated cells observed.  
Mono Tri Tetra MN_Mono MN_Bi MN_Tri MN_Tetra CBPI 
Jurkat-NT 229.3 5.46 4.55 0.91 3.64 0.00 0.00 1.8
Jurkat-P 314.96 7.87 8.86 1.97 2.95 0.00 0.98 1.83
Jurjat-7GGC 435.47 7.86 8.98 3.37 7.86 2.24 0.00 1.92
Jurkat-9GGC 372.02 6.94 10.91 1.98 3.97 0.00 0.99 1.86
Jurkat-10GGC 341.06 8.34 12.97 1.85 4.63 0.93 0.00 1.88
Jurkat-11GGC 255.42 5.92 12.82 5.92 18.74 0.00 2.96 1.89
Jurkat-12GGC 330.02 10.93 20.87 3.98 20.87 1.99 0.99 1.96
 
Mono: mononucleated cells; Tri: trinucleated cells; Tetra: tetranucleated cells; MN_Mono: mononucleated 
cells with micronucleus; MN_Bi: binucleated cells with micronucleus;  MN_Tri: trinucleated cells with 
micronucleus; MN_Tetra: tetranucleated cells with micronucleus; CBPI: cytokinesis block proliferation 
index; NT: non-transfected; P: empty plasmid  
 
 
DISCUSSION 
 
eRF3a plays a pivotal role in human cells, taking part in different major processes for cell survival. The 
eRF3a/GSPT1 gene harbours a (GGC)n stable expansion in exon 1, which codes for a Gly stretch in the 
N-terminal domain of the protein. The amino-terminal region of eRF3a was shown to be involved in its 
interaction with other proteins, which is necessary to accomplish different eRF3a functions. 
In this study we showed that the longer known allele (12-GGC), which has been associated with cancer 
development, is present in 2.2% of the colorectal cancer (CRC) patients. When we combine the results 
obtained in this study with previously published reports in other cancer models [4,5], the 12GGC allele is 
present in 5.1% of the patients (N=411) with an allele frequency of 3%, corresponding to a 12-fold 
increased risk for cancer development (OR= 11.8; SE=1.43; C.I.=0.71-195.46).  
Epidemiological evidence points to a connection between inflammation and a predisposition for the 
development of cancer, i.e. long-term inflammation leads to the development of dysplasia [27]. As many 
of the genetic and epigenetic alterations involved in IBD-associated CRC are common to sporadic 
colorectal tumors, we postulated that the 12GGC allele could be used as a predictive marker in CD 
patients. However, we failed to find the 12-GGC allele in CD patients so, this hypothesis could not be 
supported. Therefore, the 12GGC allele is not likely associated with inflammation.   
eRF3a/GSPT1 mRNA levels have been reported to be up-regulated both in intestinal type gastric tumors 
[15] and in breast tumors [5] when compared to normal adjacent tissues.  Also, patients with the 12-GGC 
allele revealed increased levels of mRNA expression when compared with the shorter alleles. However, 
the mechanism involved in eRF3a/GSPT1 over-expression was not understood. In good agreement with 
our previous study [5], here we show that the mRNA levels of eRF3a/GSPT1 expressing the 12-GGC 
allele were significantly up-regulated both in primary lymphocyte cultures of patients with different 
genotypes and in Jurkat modified cell lines expressing the 5 alleles (Jurkat-(GGC)n), when compared with 
the 10GGC allele. In the Jurkat-(GGC)n cell lines the levels of eRF3b/GSPT2 and eRF1 were also 
quantified, but no correlation between eRF3a/GSPT1 expression and the levels of mRNA of the other 
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translation termination factors could be established. This results also corroborate previously publish data 
[5,15,28] and support the idea that elevated eRF3a/GSPT1 mRNA levels are not the result of a 
coordinate up-regulation of the translation termination machinery necessary to support increased 
translation rates. 
It is now widely recognised that epigenetic modifications are a common mechanism of gene expression 
regulation via gene transcription, and that methylation of CpG dinucleotides is an important mechanism in 
the carcinogenesis process [29]. In eRF3a/GSPT1 exon 1 (GGC)n polymorphism, the number of CpG 
sites is directly proportional to the number of GGC repeats present. However, our data show that the 
GGC repeat length variation from 7 to 12 have no effect on the methylation status of this region. 
Regardless of the source of the DNA sample (tumors, normal tissues or blood, cancer patients or 
controls), all CpG sites inside the GGC expansion showed no methylation. Therefore, the methylation 
level inside the GGC expansion cannot explain differences in the levels of transcription between alleles. 
CpG islands often occur as clusters of CpG residues found in the 5’ regions of about 50% of the human 
genes. These areas are usually unmethylated in normal somatic cells, which is believed to be a 
prerequisite for active transcription [29,30]. Using the CpG Island Searcher software 
(http://cpgislands.usc.edu/), we found that the GGC expansion is localized inside a 1195bp CpG island 
(64.5%GC; ObsCpG/ExpCpG=0.898) that spans part of the 5’UTR, the entire exon 1 and part of intron 1 
in eRF3a/GSPT1 gene (data not shown).  The remaining CpG sites in this island should therefore be 
analysed and correlated with the expression of the gene. 
DNA copy number gains and losses are often responsible for aberrant gene expression patterns 
associated with malignancy. An example of this is HER2 gene amplification, a common event in breast 
cancer, leading to overexpression of the protein in about 20% of the patients [31,32]. eRF3a/GSPT1 gene 
copy dosage was determined in DNA samples from tumors and normal tissues of individuals with all 
possible genotypes, but no correlations were found between gene copy dosage and mRNA levels of 
expression. No amplifications of eRF3a/GSPT1 were detected in any of the samples analysed, namely in 
the samples with the 12-GGC allele. These results reveal that other mechanisms must be responsible for 
the elevated levels of eRF3a/GSPT1 mRNA found in a significant proportion of both gastric and breast 
tumors.  
Although the signalling pathways and the proteins involved are still not identified, it was shown that 
eRF3a depletion inhibits not only translation but also the cell cycle progression in HCT116 cell line, via 
mTOR pathway inhibition [10]. The mTORC1 controls the level of cap-dependent mRNA translation by 
modulating the activity of key translational components. It is known that eIF4E and S6K activity is 
enhanced in several cancer cell lines and human tumors due to the increase of mTOR activity [33]. The 
efficiency of eRF3a as a translation termination factor was already shown not to be affected by the length 
of the glycine expansion in the N-terminal domain of the protein [5]. In this study, we showed that the 
length variation of the glycine expansion from 7 to 12 in eRF3a N-terminal also has no effect on the cell 
cycle progression, as reflected by the Proliferation Index (S+G2M) and the percentage of cells in the S-
Phase of the cell cycle, neither in lymphocyte cultures nor in Jurkat-(GGC)n cell lines.  
eRF3a also acts as a regulator of apoptosis being proteolytically processed into an isoform that contains 
a conserved N-terminal IAP-binding motif [11,34]. Disturbance of the correct interaction/ balance between 
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eRF3a and IAPs can release these proteins and consequently repress or even block the apoptosis 
pathways in which they are involved. Although the polymorphic glycine stretch is not present in the 
processed isoform of eRF3a, since it is part of the 69 N-terminal residues excluded by proteolytic 
cleavage, we raised the hypothesis that the number of glycine residues might interfere in the cleavage 
process. To test for this possibility, we quantified the levels of apoptosis in cells expressing proteins with 
7-12 Gly in the N-terminal domain. Our observation that the percentage of viable cells, dead cells and 
total apoptotic cells was not significantly different over the range of 7-12 Gly residues suggests that this 
range of repeat lengths is optimal for eRF3a activity as a IAP-binding protein.  
Using different organisms as study models, eRF3 was shown to affect cytoskeleton assembly. eRF3 was 
shown to affect the tubulin cytoskeleton, suggesting a role in the control of chromosome segregation at 
the anaphase [13]. Its involvement in the assembly of the actin cytoskeleton in yeast was also 
demonstrated [14], affecting the impairment of the mitotic spindle structure and segregation. Deregulation 
of eRF3 expression also resulted in abnormal meiotic chromosome segregation and defects in the 
cytoskeleton assembly in spermatids of Drosophila melanogaster [12]. Regulation of microtubules 
dynamics, the key components of the cytoskeleton, is crucial for mitosis, cell migration, cell signalling and 
trafficking. The formation of micronuclei (MN) in dividing cells is the result of chromosome breakage due 
to unrepaired or mis-repaired DNA lesions, or chromosome malsegregation due to mitotic malfunction. 
MN frequency is therefore considered a predictive biomarker of cancer risk [35]. We used the frequency 
of MN as a biomarker of chromosomal damage and genome stability. Our results show that the formation 
of MN is more frequent in cell lines with longer GGC expansions, with a maximum value in cells 
expressing the 12GGC allele, both in the Jurkat-(GGC)n cell lines and in the primary lymphocyte cultures. 
These results may be indicative that the encoded proteins could induce malsegregation of 
chromatids/chromosomes by interfering with the accurate functioning of the mitotic spindle. It is known 
that in cancer cells, centrosomes are often found amplified to greater than two per cell, resulting in an 
increased frequency of chromosome segregation errors (chromosome instability). Destabilization of 
chromosomes by centrosome amplification aids acquisition of further malignant phenotypes, hence 
promoting tumor progression [36]. In accordance, several studies have reported increased MN 
frequencies in peripheral lymphocytes from cancer patients when compared with matched control 
populations [37,38]. 
In summary, we have investigated the gene expression profiles induced by different alleles of 
eRF3a/GSPT1 gene. Our results show that the significant up-regulation in gene expression associated 
with the 12-GGC allele may be the primary effect of eRF3a-mediated oncogenesis. Further, our data 
suggests a greater chromosomal damage resulting from mitotic spindle defects in cells expressing 
eRF3a-12GGC. These patterns highlight the distinct functions of the individual alleles of eRF3a/GSPT1 
and may contribute to the developmental and oncogenic roles of eRF3a/GSPT1. The translation of the 
present results to clinical practice remains a challenge but carries the promise of more effective 
diagnostic, prognostic and medical treatment strategies for cancer. 
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4. CHAPTER IV 
DISCUSSION 
 
 
This chapter presents an integrative discussion of the results obtained in the 5 papers that 
compose Chapters II and III of this dissertation (Malta-Vacas et al., 2005; Brito et al., 2005; 
Malta-Vacas et al., 2009a; Malta-Vacas et al., 2009b; Malta-Vacas et al., submitted). 
 
 
The concept that genetic variation underlies inter-individual differences in drug response and 
contributes to the risk of developing common complex disorders is expanding rapidly. 
Consequently, the interest in genetic translational research has increased. A great proportion of 
the success observed in Mendelian disease mapping was due to the strong heritability of the 
traits in families and the fact that mutation of a single gene was, for most diseases, the driving 
force behind disease pathogenesis; in almost all instances, a strong genotype–phenotype 
correlation could be drawn. Complex diseases do not necessarily follow traditional patterns of 
Mendelian inheritance. So, the identification of disease causing genes using conventional linkage-
based approaches has been less successful (Iyengar & Elston, 2007; Bodmer & Bonilla, 2008). 
Recent advances in high-throughput genotyping technology, and a better understanding of the 
genetic architecture of complex disease has led to the development of genome-wide association 
studies (GWA), which are providing now novel and important insights into disease processes 
(Hirschhorn & Daly, 2005; Lango & Weedon, 2008). 
In the field of oncogenetics, two types of polymorphisms have been extensively studied: single 
nucleotide polymorphisms (SNPs) and short tandem repeats (STRs), with particular regard to 
trinucleotide repeats. Microsatellite alterations such as microsatellite instability (MSI) and loss of 
heterozygosity (LOH) gained a lot of interest (De Schutter et al., 2007; Zhang & Yu, 2007; Imai 
& Yamamoto, 2008). Furthermore, gene expression profiling using DNA microarrays is likely to 
become a useful diagnostic tool enabling classification of disease phenotype based on molecular 
basis of disease pathogenesis, revealing information that cannot be obtained by histological 
assessment. Moreover, identification of differentially expressed genes in affected versus control 
tissue or over time in affected tissue will lead to better understanding of the mechanisms 
underlying disease and ultimately to the development of more effective drug therapies. 
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4.1 Translation and cancer 
 
The eukaryotic cells have a variety of means by which they are able to regulate the expression of 
their genes. Although transcriptional regulation is obviously crucial, the control of gene 
expression also relies heavily on translational selectivity and the mechanism of protein synthesis 
provides the cell with a variety of sophisticated and subtle means to modulate the rates of 
production of key proteins (Clemens, 2004, Gebauer & Hentze, 2004; Kapp & Lorsch, 2004; 
Mata et al., 2005). This reflects the necessity for rapid adaptations of the gene expression 
system to alterations of cellular conditions, such as re-entry into cell cycle. 
As the molecular processes that control mRNA translation in the eukaryotic cells are extremely 
complex and highly integrated with the cell cycle control, their deregulation can occur at multiple 
levels, leading to disease and particularly to cancer pathogenesis (Clemens & Bommer, 1999; 
Dua et al., 2002; Abbott & Proud, 2004; Holland, 2004; Pandolfi, 2004; Bilangues & Stokoe, 
2007). Molecular links between tumor-suppressive and oncogenic pathways and the control of 
protein synthesis machinery have been revealed in the past decades.  
Until recently, the notion that translational control could be a driving force of the oncogenic 
process was not generally accepted, being the translation machinery regarded as a passive 
recipient of aberrant signalling cues (Ruggero & Pandolfi, 2003; Holland et al., 2004). Strong 
genetic support is now being accumulated for the opposite hypothesis, in which the protein 
machinery itself would be missfunctional, leading to cancer. This includes (i) the identification of 
alterations in the expression of several genes encoding proteins known to modulate mRNA 
translation that are associated with cancer (Nupponen et al., 1999; Joseph et al., 2004; 
Savinainen et al., 2004; Comtesse et al., 2007; Tomlinson et al., 2007; Rojo et al., 2007), (ii) 
antisense mRNA-mediated reduction of the expression of certain translation factors that resulted 
in a reversion of the oncogenic properties of the cancer cells (Li et al., 2006; Graff et al., 2007), 
(iii) effective anticancer drugs proven to act on key regulators of the protein synthetic machinery 
(Mita et al., 2003; Easton & Houghton, 2006), and mainly (iii) ectopic expression of certain 
translation factors that resulted in cell transformation and tumorigenesis (Anand et al., 2002; De 
Benetti & Graff, 2004). 
In the past years, much attention has been paid to initiation and elongation translation factors 
(de)regulation and their role in malignancy (Meric & Hunt, 2002; Stoneley & Willis, 2003; 
Sonenberg & Dever, 2003; Averous & Proud, 2006; Sun et al., 2008; Tejada et al., 2009). In 
what concerns translation termination, only a few studies have analyzed their expression profile 
in cancer tissues. Zondervan et al. (2000) suggested eRF3b/GSPT2 (among other genes) as a 
candidate gene for hepatocellular carcinoma susceptibility. A few years later Thakur et al. (2005) 
showed that eRF3b/GSPT2, as well as other genes related to ribosomal biogenesis and 
translational control, presented 2-fold or higher expression in transgenic mouse mammary 
tumors compared to lactating mammary gland. Groene et al. (2006) also identified eRF3b/GSPT2 
and the gene encoding the transcription factor HOXA9 as the most relevant elements in a 45 
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gene signature that allowed discrimination between UICC (international union against cancer) 
stage II and stage III colorectal cancers, with a rate of correct classification of about 80%. 
However, there was no differential expression of genes in cancer-related pathways. Only one 
study analyzed the expression profile of a series of 36 translation factors, including initiation, 
elongation and termination factors, to assess differences in mRNA levels between tumor and 
normal cell lines (Joseph et al., 2004). Unfortunately, only one termination factor was 
represented, eRF1, which revealed no variation between tumor and normal cells.  
Our own results show that eRF3a/GSPT1 is significantly over-expressed both in intestinal type 
gastric tumors (Malta-Vacas et al., 2005) and in breast tumors (Malta-Vacas et al., 2009a). 
However, in both cases, eRF3a/GSPT1 gene expression was shown not to be correlated with the 
levels of expression of the other translation termination factors, and therefore was not 
associated with increased translation rates. eRF3a/GSPT1 gene expression will be discussed in 
Chapter 3.3 of this thesis. 
 
 
4.2 eRF3a/GSPT1 DNA polymorphisms  
 
The gene eRF3a/GSPT1 contains a (GGC)n stable expansion in exon 1, which encodes a 
polyglycine stretch in the N-terminal domain of eRF3a protein. Four alleles, containing 7, 9, 10 
and 11 GGC repeat units, were detected in our control population composed of healthy 
individuals with no known familiar history of cancer. The same four alleles were detected in a 
Crohn’s Disease sample population. An extra allele with 12GGC repeat units was exclusively 
detected in cancer patients, with an allele frequency of 5% in gastric (Brito et al., 2005), 2,55% 
in breast (Malta-Vacas et al., 2009a) and 1,09% in colorectal cancer (Malta-Vacas, submitted). 
When the results obtained in all the cancer patients samples analysed are combined, the 12GGC 
allele is present in 5,1% of the patients (N=411) with an allele frequency of 3%, corresponding 
to a 12-fold increased risk for cancer development (OR= 11,8; SE=1,43; C.I.=0,71-195,46). 
Although the odds are not statistically significant, the considerable increased risk associated with 
this allele should not be, in our view, considered as insignificant. Given the rarity of the allele, 
the statistical results need to be strengthened by replication in larger populations. 
 
4.2.1. eRF3a/GSPT1 polymorphisms in cancer 
 
Microsatellite alterations such as microsatellite instability (MSI) and loss of heterozygosity (LOH) 
gained a lot of interest as possible tumor markers. Microsatellite regions are at high risk for 
variations in the number of repeats caused by slippage of the DNA polymerase during DNA 
replication. In normal cells, these errors are repaired by the mismatch repair system (MMR). In 
tumors, defects in the MMR system may be present, so that variations in microsatellite regions 
are not repaired correctly, leading to somatic changes with gain or loss of repeat units. Thus, 
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MSI is generally associated with the presence of a defect MMR system, although environmental 
factors might also have a role in generating it (De Schutter et al., 2007). Interestingly, Alvarado 
et al., (2005) showed some genetic heterogeneity (somatic mosaicism) for the androgen 
receptor (AR) gene CAG repeat length in laser capture microdissected prostate cancer samples, 
which was not present in normal prostate tissues. The same pattern was observed by Di Fabio et 
al., (2008) in colorectal carcinoma epithelial cells from men. However, there was no significant 
difference in the allele lengths between MSI carcinomas and microsatellite stable carcinomas, 
revealing that multiple unique somatic mutations of the AR CAG repeats occur. A significant 
shortening of the CAG repeat lengths was observed in cancerous tissues, which may be 
responsible for the generation of highly proliferating clones of cancer cells characterized by 
increased responsiveness to androgens. Thus, we have considered the possibility that 
eRF3a/GSPT1 genetic heterogeneity could also exist. To evaluate this, we compared the GGC 
repeat lengths of eRF3a/GSPT1 microsatellite alleles between normal and tumor tissues in gastric 
cancer samples but no evidence for MSI or somatic mosaicism  was detected (Brito et al., 2005). 
LOH marks a suppressor phenotype that is characterized by extensive losses of genetic material. 
Accordingly, LOH can be recognized by loss of a genomic fragment, SNP or microsatellite allele in 
a tumor when compared with normal tissue. LOH in eRF3a/GSPT1 microsatellite was investigated 
but not detected in gastric cancer tissues (Brito et al., 2005). Furthermore, we determined 
eRF3a/GSPT1 gene copy dosage in normal and tumor gastric and CCR samples. Only looses of 
genetic material were found in gastric cancer tissues from three patients (Malta-Vacas et al., 
2005), but were not associated to LOH, since they were homozygous in this locus. Accordingly, 
looses in chromosome 16p have been reported in gastric (Sarlomo-Rikala et al., 1998; Takeno et 
al., 2009) and other types of cancer (dos Santos Aguiar et al., 2007; Ross et al., 2007; 
Rydzanicz et al., 2008). Gains on chromosome 16p have also been reported in some types of 
cancer, including gastric cancer cell lines (Takada et al., 2005). However, we did not detect 
amplifications of eRF3a/GSPT1 gene in gastric tumors or CCR tissues (Malta-Vacas et al., 2005; 
Malta-Vacas et al., submitted). 
Several exonic trinucleotide repeats have been associated with oncological pathologies, either 
conferring a protective effect or associated with elevated risk for disease (see Table 4 in Chapter 
1.5 of this thesis). The most investigated STR in cancer is the CAG repeat expansion in the AR 
gene. Laboratory experiments show that the length of this repeat expansion affects the activity 
of gene transcription (i.e., the longer the repeats the lower the transactivation). Based on this 
finding, it is speculated that prostate cancer risk may vary with the length of CAG repeats due to 
the role of androgen receptor in the disease (Tran et al., 2004; Zhang & Yu, 2007). This 
speculation has been supported by some epidemiologic studies in which longer CAG repeats are 
found to be associated with lower risk of prostate cancer in populations of different geographical 
origins (Hsing et al., 2002; Nelson & Witte, 2002; Krishnaswamy et al., 2006). However, 
inconclusive and even conflicting results have been achieved in other studies, so there is not a 
consensual opinion about the role of this CAG expansion in cancer (Li et al., 2003; Zeegers et al., 
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2004; Lange et al., 2008). The exon 1 of AR gene also contains a GGC expansion, the length of 
which has been shown to be inversely associated with breast (Suter et al., 2003) and prostate 
cancer risk (Chang et al., 2002; Ding et al., 2005). However, the functional significance of this 
GGC trinucleotide polymorphism has not been extensively examined. 
A few other studies also reveal that microsatellites may have functional roles in transcription. A 
tetranucleotide polymorphic microsatellite located in the first intron of the tyrosine hydroxylase 
(TH) gene is implicated in the regulation of TH gene expression (Meloni et al., 1998). The Pig3 
gene harbors a pentanucleotide microsatellite (TGYCC)n in its promoter that functions as a p53 
binding site. This microsatellite is polymorphic, and the expression level of Pig3 by p53 correlates 
with the length of the microsatellite (Contente et al., 2002). This polymorphism was shown to be 
associated with an increased risk for bladder cancer (Ito et al., 2006) but not for breast and lung 
cancer susceptibility (Gorgoulis et al., 2004). Recently, the EWS/FLI oncogenic transcription 
factor involved in Ewing’s sarcoma was shown to interact with (GGAA)n microsatellites to 
regulate some of its target genes (Gangwal et al., 2008). An association between the number of 
GGAA repeats and EWS/FLI binding and transcriptional activity was confirmed for different genes. 
For that reason, the authors raised the hypothesis that those microsatellite polymorphisms may 
be responsible for differences in susceptibility to Ewing’s sarcoma, both between individuals and 
between populations (Gangwal & Lessnick, 2008). 
Unfortunately, the promoter and 5‘UTR regions of eRF3a/GSPT1 gene are still not well 
characterized. Also, the cis-acting elements and transcription factors involved in the induction of 
human eRF3a/GSPT1 transcription remain to be identified. However, based on the results 
described above, it is tempting to speculate that the same phenomena might occur and that the 
microsatellite polymorphism in eRF3a/GSPT1 exon 1 is associated with the individual 
susceptibility for cancer development by affecting the binding efficiency of transcription factors. 
If the length of the GGC expansion in eRF3a/GSPT1 affects the binding of putative transcription 
factors or other cis-acting proteins, the level of transcription will be proportional to the number 
of GGC repeats present. Therefore, individuals with longer (or shorter) alleles might present a 
greater (or lower) susceptibility to cancer. In this case, differences in allele frequencies between 
different populations would also reflect different population susceptibilities to cancer. 
DNA methylation, especially in promoter regions, is a possible mechanism of regulation of gene 
expression, either directly interfering with the binding of transcription factors, or indirectly, 
causing changes in chromatin conformation (Esteller, 2007). The number of GGC repeats in 
eRF3a/GSPT1 microsatellite is proportional to the number of CpG sites present. CpG islands, 
generally defined as a 200-bp minimum stretch of DNA with a C+G content greater than 50% 
and an observed CpG/expected CpG in excess of 0.6. (Takai & Jones, 2002) often occur as 
clusters of CpG residues found in the 5’ regions of about 50% of the human genes. These areas 
are usually unmethylated in normal somatic cells, which is believed to be a prerequisite for 
active transcription (Dunn, 2003; Esteller, 2007). It is now widely recognised that epigenetic 
modifications are a common mechanism of gene expression regulation via gene transcription, 
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and that methylation of CpG dinucleotides is an important mechanism in the carcinogenesis 
process (Esteller, 2007). In eRF3a/GSPT1 exon 1 (GGC)n polymorphism, the number of CpG 
sites is directly proportional to the number of GGC repeats present. However, our data show that 
the GGC repeat length variation from 7 to 12 have no effect on the methylation status of this 
region. Regardless of the source of the DNA sample (tumors, normal tissues or blood; cancer 
patients or control individuals), all CpG sites inside the GGC expansion are unmethylated (Malta-
Vacas, submitted). Therefore, the methylation level inside the GGC expansion cannot explain 
differences in the levels of transcription between alleles. Using the CpG Island Searcher software 
(http://cpgislands.usc.edu/), we found that the GGC expansion is localized inside a 1195bp CpG 
island (64,5%GC; ObsCpG/ExpCpG=0.898) that spans part of the 5’UTR, the entire exon 1 and 
part of intron 1 in eRF3a/GSPT1 gene. The remaining CpG sites inside this CpG island should 
therefore be analysed in each microsatellite allele and correlated with the expression of the gene. 
We further investigated the presence of additional genetic variability in eRF3a/GSPT1 gene that 
could be linked with the polyglycine expansion polymorphism. Only two synonymous SNPs are 
described within the coding sequence of eRF3a/GSPT1 in the NCBI database: T1128C located in 
exon 7 (rs33657) and G1986C located in exon 14 (rs3752426). We additionally detected a 
nucleotide substitution G274T in exon 1, resulting in an amino acid change from Gly to Cys at 
codon 92. Although genetic databases revealed that Gly is a conserved amino acid at this 
position among different species, our results provided evidence to support that this is a 
polymorphism rather than a new mutation (Brito et al., 2005). Therefore, this polymorphism was 
screened in cancer patients and control individuals, but no differences in the frequencies 
between both groups were detected (χ2=0.04; P>0.05). Odds ratio (OR) analysis failed to reveal 
any risk/protective effect associated with either allele. Moreover, after a linkage analysis we 
concluded that the polymorphisms analysed did not segregate with any of the alleles of the 
polyglycine expansion. 
Most of the studies done so far on the role of STR alleles contribution to cancer highlighted 
individual variations in cancer risk, associated with specific alleles of different polymorphic genes 
that are present in a significant proportion of the normal population. Conversely, we report the 
presence of a specific allele (12GGC) directly associated with cancer development. Therefore, we 
purpose that the presence of the 12GGC allele, by itself, may provide a new useful marker for 
cancer susceptibility. 
 
4.2.2. eRF3a/GSPT1 microssatelite polymorphism in inflammation 
 
Epidemiological evidence points to a connection between inflammation and a predisposition for 
the development of cancer, i.e. chronic and persistent inflammation leads to the development of 
neoplasia (Allavena et al., 2007). Crohn’s disease (CD) is a chronic inflammatory disease that 
can affect the entire gastrointestinal tract from the mouth to the anus. Nowadays, the 
association between CD and the increased risk for CRC is widely accepted (Zisman & Rubin, 
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2008). CRC is the most common type of cancer in inflammatory bowel disease (IBD), although 
cancer in other organs can occur. Although CRC associated to IBD accounts only for 1%-2% of 
all cases of CRC in the general population, it is considered a serious complication of these 
diseases and accounts for approximately 10%-15% of all deaths in IBD patients (Munkholm, 
2003). CD is a complex disease in which multiple genetic and environmental factors are likely to 
contribute to pathogenesis, and the search for CD susceptibility genes therefore poses similar 
problems to those in other complex disorders.  As several of the molecular alterations that are 
involved in IBD-associated CRC are common to sporadic colorectal tumors (Zisman & Rubin, 
2008), we postulated that the 12GGC allele could be used as a predictive marker in CD patients. 
However, we failed to find the 12GGC allele in CD patients so this hypothesis could not be 
supported. Therefore, the 12GGC allele is not likely associated with inflammation. Moreover, 
there were no significant differences in the frequencies of the alleles between CD patients and 
control healthy individuals.  
 
 
4.3. eRF3a/GSPT1 gene expression 
 
eRF3a/GSPT1 gene is ubiquitously expressed in mammalian cells. The expression of the gene is 
proliferation dependent, being the mRNA levels up-regulated in the G1 to S phase transition of 
the cell cycle (Hoshino et al., 1989; Hoshino et al., 1998). Low levels of mRNA were detected in 
liver cells (Hoshino et al., 1989) and a strong decrease during human chondrocytes 
differentiation has been reported (Tallheden et al., 2004). Chauvin et al. (2005) showed that the 
level of eRF3a protein controls the formation of the translation termination complex. In this 
study they show that eRF1 intracellular levels are adjusted to that of the eRF3a available for the 
formation of translation termination complexes. The opposite situation was not verified, 
suggesting that, due to its involvement in other cellular processes and association with other 
factors, the intracellular amount of eRF3a is controlled by mechanisms other than the 
termination complex formation.  
When investigating the patterns of eRF3a/GSPT1 gene expression in cancer, comparing the 
levels of mRNA in tumors with the normal adjacent tissues, we found that the gene is frequently 
over-expressed in tumor tissues, regardless of the type of cancer analyzed (Malta-Vacas et al., 
2005; Malta Vacas et al., 2009a).  
In what concerns gastric cancer, we have shown that eRF3a/GSPT1 is over-expressed in 67% of 
the intestinal gastric tumors and only in 10% of the diffuse type tumors. The difference in the 
pattern of expression of eRF3a/GSPT1 supports the hypothesis of genetically independent 
pathways in the origin of intestinal and diffuse type gastric tumors (Werner et al., 2001; Zheng 
et al., 2004; Cervantes et al., 2007). Lower proliferating rates have been assigned to intestinal 
tumours using different labeling indexes (Shinohara et al., 1996; Seno et al., 2002; Cervantes et 
al., 2007). Therefore, it seems unlikely that the higher amounts of eRF3a/GSPT1 mRNA seen in 
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intestinal type tumours are necessary for increased translation rates, which could be expected in 
cancer cells to support higher proliferation activity. Accordingly, the transcript levels of 
eRF3a/GSPT1 were not correlated with those of eRF1 and eRF3b/GSPT2 and therefore were not 
associated with increased translation rates (Malta-Vacas et al., 2005). 
Regarding breast cancer, we found eRF3a/GSPT1 overexpressed in 44% of the tumors. We 
further compared the patterns of expression between invasive ductal carcinomas (IDC), which is 
the most common type of breast cancers, and other types of tumors, but no differences between 
different types of tumors were detected. Once again, the mRNA levels of eRF3a/GSPT1 were not 
correlated with the levels of the other translation termination factors. In this study, analyzing 
breast cancer patients, we had the first indication that the level of mRNA expression of 
eRF3a/GSPT1 gene could be correlated with the length of the GGC expansion in exon 1. The 
longer allele (12GGC) was only found in patients with eRF3a/GSPT1 overexpression in tumor 
samples. In contrast, the shorter allele (7GGC) was mostly associated to tumors with 
eRF3a/GSPT1 underexpression (Malta-Vacas et al., 2009a). 
Allelic specific gene expression is a widespread mechanism in the human genome whose 
regulation seems to be far more complex than expected. It appears to be an important factor in 
human phenotypic variability and as a consequence, for the development of complex traits and 
diseases (Palacios et al., 2009). In order to test the hypothesis that the allele length in the 
microsatellite polymorphism in eRF3a/GSPT1 exon 1 has a role in transcription regulation, we 
obtained different cell lines with all the known alleles, in order to quantify the levels of gene 
expression induced by each allele. 
We have measured the transcript levels of eRF3a/GSPT1 in primary lymphocyte cultures from 
patients with different genotypes and in Jurkat lymphoblastoid cell lines modified to express each 
different allele. Significant allelic expression imbalance (AEI) was detected in both. The mRNA 
levels of eRF3a/GSPT1 expressing the 12GGC allele were significantly up-regulated both in 
primary lymphocyte cultures (7.6-fold higher) and in Jurkat modified cell lines (12-fold higher), 
when compared with the respective reference 10GGC allele. In the Jurkat cell line expressing the 
9GGC allele, the mRNA level was significantly lower, when compared with the reference Jurkat-
10GGC cell line (Malta-Vacas et al., submitted). Overall, we detected a direct relation between 
the level of eRF3a/GSPT1 gene expression and increased number of GGC repeats. These results 
could not corroborate those of other published studies, in which "long" GGC alleles within stable 
expansions significantly decrease gene expression, either affecting transcription (Persico et al., 
2006) or translation (Ding et al., 2005) of the genes harboring them.  
It is possible, as discussed before, that cis-acting regulatory factors might be affected by the 
length of the GGC expansion, increasing the level of transcription of longer alleles. Consequently 
the transcripts reach levels of oncogenecity, through a mechanism not yet identified. 
Furthermore, there is also the possibility that the longer 12GGC allele encodes a mutant protein 
with transforming proprieties itself.  
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4.4. eRF3a/GSPT1 as a proto-oncogene 
 
The mechanism of eRF3a/GSPT1 overexpression in cancer tissues is still not elucidated. 
However, in the view that eRF3a is closely regulated by conditions that affect cellular 
proliferation (Hoshino et al., 1989; Hoshino et al., 1998; Chauvin et al., 2007), it is not 
surprising that aberrant expression of eRF3a/GSPT1 gene induce malignant transformation of 
cells. Although the mechanism by which transformation occurs has not been established, it is 
consensually assumed that elevated expression of key regulatory proteins is involved in 
carcinogenesis.  
 
4.4.1 eRF3a roles in translation 
 
Whether the oncogenic event happens upstream the ribosome or it is eRF3a/GSPT1 
intrinsic/specific, overexpression of the gene may theoretically lead to: i) a global impairment of 
mRNA translation (overall increase in the rate of protein synthesis), (ii) selective quantitative 
defects in mRNA translation (increase in the synthesis of specific mRNA targets) or iii) qualitative 
defects in protein translation (mistranslation). The three possibilities are discussed below, 
regarding the roles of eRF3a in translation. 
The protein synthesis is coupled with cell cycle progression and is regulated in response to 
nutrient availability and mitogenic stimulation. However, the transduction pathways activated do 
not stimulate the translation of all the mRNAs equally. The expression of the components of the 
translation machinery might be selectively regulated, increasing the translation rate of specific 
oncogenic transcripts (Dua et al., 2001; Holland, 2004; Holland et al., 2004; Rajasekhar & 
Holland, 2004; Mamane et al., 2007). Although the signalling pathways and the proteins 
involved are still not identified, it was recently demonstrated that eRF3a depletion in HCT116 
cells induces an arrest of the cell cycle in late G1 phase, via mTORC1 inhibition (Chauvin et al., 
2007). The mTORC1 controls the level of cap-dependent mRNA translation by modulating the 
activity of key translational components. After activation by mTOR, S6K phosphorylates the 
ribosomal protein S6, leading to an increase in translation of a subset of mRNAs (Corradetti & 
Guan, 2006). It is known that eIF4E and S6K activity is enhanced in several cancer cell lines and 
human tumours due to the increase of mTOR activity (Averous & Proud, 2006). Therefore, it is 
tempting to speculate that eRF3a/GSPT1 overexpression detected in different kinds of tumors 
might be responsible for excessive mTOR activation, leading to differential expression of specific 
targets and consequent malignant transformation.  
The mTOR pathway has been extensively studied in the past decades because rapamycin, a 
specific inhibitor of mTOR activity, was shown to have a potent anti-cancer activity. However, it 
is known that not all effects of mTOR are sensitive to the classical anti-mTOR drug rapamycin, 
and this compound also interferes with other processes besides eIF4E function (Averous & Proud, 
2006). Signaling by the PI3K/Akt/mTOR pathway profoundly affects mRNA translation through 
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phosphorylation of downstream targets such as 4E-BP and S6K. Inhibitors of this pathway and 
thus cap-dependent translation are emerging as promising therapeutic targets for cancer therapy 
(Averous & Proud, 2006; Mamane et al., 2006). Such molecules are likely to come from further 
work to understand the regulation of mTOR targets such as components of the translational 
apparatus. In this context, eRF3a/GSPT1 comes out as a potential candidate target molecule for 
cancer treatment. 
eRF3 interacts with poly(A)-binding protein (PABP1) and the surveillance factor UPF1, acting as a 
key mediator that transduces termination signal to mediate normal and nonsense-mediated 
mRNA decay (Hoshino et al., 1999a; Hoshino et al., 1999b; Hosoda et al., 2003; Kobayashi et 
al., 2004). 
Interaction between eRF3a and PABP results in the inability of the latter to multimerize and 
consequently inhibits it to perform the typical regularly spaced complexes on the poli(A) tail of 
mRNAs that regulate mRNA degradation. This may facilitate shortening of the poly(A) tail of 
mRNAs by an RNase (Hoshino et al., 1999a; Hoshino et al., 1999b; Hosoda et al., 2003). 
Therefore, enhanced amounts of eRF3a in the cells, as a consequence of eRF3a/GSPT1 
overexpression, might result in the recruitment of high amounts of PABP, which consequently 
becomes scarce to generate the multimeric complexes that regulate mRNA stability and mRNA 
turnover. Although we do not have own results/ data to support this hypothesis, it is tempting to 
speculate that this process could lead to a global increase in mRNA instability. Furthermore, it is 
reasonable to assume that the termination signal triggers mRNA degradation. If mRNA 
degradation starts while translation is still in progress, deleterious truncated proteins may be 
synthesized.  
By interacting with PABP, eRF3a was also reported to have a role in the circularization of the 
mRNA, allowing the recycling of ribosomes for successive translation cycles. The terminating 
ribosome could be passed to the 5’ cap structure through a protein bridge consisting of eRF1-
eRF3-PABP-eIF4F (Uchida et al., 2003; Hosoda et al., 2003). The inhibition of the interaction 
between eRF3a and PABP was shown to significantly attenuate translation of capped/poly(A)-
tailed mRNA (Hoshino et al., 1999a). Therefore, one can foresee that alterations in the levels of 
expression of eRF3a/GSPT1 can modulate translation of capped/poly(A)-tailed mRNAs, resulting 
in an impairment of mRNA translation. 
The protein eRF3a also takes part on the “surveillance complex” that triggers nonsense mediated 
mRNA decay (NMD), a mechanism that recognizes mRNAs containing premature termination 
codons (PTCs) and induces their degradation. These transcripts are generally derived from genes 
in which a mutation has given rise to a premature nonsense codon, but the PTC can also be 
attributable to errors in transcription, pre-mRNA splicing or RNA editing (Amrani et al., 2006). 
PTCs are known to cause at least some of the diseases that involve protein insufficiency, namely 
oncological pathologies. The biological and medical significance of NMD is highlighted by an 
increasing number of known genetic diseases that are caused by C-terminally truncated proteins, 
such as the Hurler syndrome, muscular dystrophy and cystic fibrosis (Boikos & Stratakis, 2006; 
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Brooks et al., 2006; Khajavi et al., 2006; Linde & Kerem, 2008). The NMD represents a 
translation-dependent process that selectively recognizes and degrades mRNAs whose open 
reading frame (ORF) is truncated by a PTC and consequently encodes incomplete polypeptides. 
The truncated proteins encoded by these mutant mRNAs are potentially toxic to the cell, either 
trough dominant-negative or gain-of-function effects. The core NMD “surveillance complex” 
consists of UPF1, UPF2, UPF3, the release factors eRF1 and eRF3 and is also affected by the 
termination codons context and exon–exon junctions’ proximity. Thus, enhanced expression of 
eRF3a/GSPT1 and consequent excess of eRF3a protein might disturb the formation of the 
surveillance complex and therefore contribute to a reduction of its efficiency, leading to the 
accumulation of truncated proteins in the cell. 
The potential oncogenic properties of eRF3a/GSPT1 discussed above arrive from a disruption in 
the normal balance between eRF3a and its interaction proteins. This results in the disturbance of 
the formation of the complexes in which eRF3a takes part, and consequently compromise their 
efficiency. Instead of quantity issues, the transforming capacities of eRF3a might also arrive from 
a protein quality basis, caused by non-functional or toxic eRF3a proteins. We consider this 
possibility specifically for the 12-Gly eRF3a protein, and its consequences will be discussed 
bellow.   
The canonical role of eRF3a is to stimulate eRF1 activity in translation termination. eRF3a 
depleted cells reveal a high level of stop codon readthrough, which is alleviated by restoring 
eRF3 expression, proving that eRF3a has a key role in translation termination efficiency (Chauvin 
et al., 2005). Although the interaction between eRF3a and eRF1 is mediated through the C-
domain of both proteins, Chauvin et al. (2005) demonstrated that the N-terminal domain could 
have an effect in the binding efficiency, possibly by blocking the site of interaction. In order to 
investigate the efficiency of eRF3a proteins with different N-terminal sizes (determined by the 
number of Gly residues) we compared the readthrough level between HEK293 cells expressing 5 
different alleles of eRF3a/GSPT1 with 7, 9, 10, 11 and 12 GGC repeat units in the first exon 
microsatellite. Our results show no significant differences in the readthrough efficiencies 
whatever the eRF3a variant expressed. This suggests that the length of the glycine stretch 
encoded by the GGC repeat has no detectable effect on eRF3a activity in what concerns its role 
in translation termination (Malta-Vacas et al., 2009a). 
Non-translational roles of eRF3 have been reported. Investigations into those functions of eRF3a 
protein shed new light on the mechanisms of its oncogenicity.  
 
4.4.2. eRF3a role in cytoskeleton dynamics 
 
eRF3a proteins, in addition to their role in translation, are thought to be involved in cytoskeletal 
regulation. The cytoskeleton of a eukaryotic cell is composed of long polymers of actin proteins 
called microfilaments, tubulin polymers termed microtubules and a heterogeneous group of 
intermediate filament proteins. These structures provide structural integrity to a eukaryotic cell 
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and regulate mitosis, cell migration, cell signaling and trafficking (Honore et al, 2005). eRF3 
proteins from several species associate with the cellular actin network and can bind tubulin 
microtubules (Basu et al., 1998; Bailleul PA, 1999; Borchsenius et al., 2000; Valouev et al., 
2002 ). The ability of eRF3a protein to interact with and/or bind to actins and tubulins raises the 
possibility that cytoskeleton alterations may facilitate tumorigenesis. 
Using different organisms as study models, eRF3 has been shown to affect both tubulin and actin 
elements of the cytoskeleton. Mutations in eRF3 have been reported to induce disruption of 
chromosome behaviour during the meiotic divisions, problems in aster formation, aberrations in 
spindle organization and disappearance of the ana/telophase central spindle, which in turn 
disrupts cytokinesis (see Chapter 1.3.3 of this thesis). The CCT complex is an important pathway 
that regulates microtubules stability and, consequently, cytoskeleton organization. An interaction 
between eRF3 and CCT (chaperonin containing TCP-1) subunits was first predicted using a 
theoretical model (Marcotte et al., 1999), and latter experimentally confirmed by 
immunoprecipitation (King et al., 2000).  
Regulation of microtubules dynamics, the key components of the cytoskeleton, is crucial for 
mitosis. During mitosis, two centrosomes form spindle poles and direct the formation of bipolar 
mitotic spindles, which is an essential event for accurate chromosome segregation into daughter 
cells (Walczak & Heald, 2008). Deregulation of centrosome structure is an integral aspect of the 
origin of chromosomal instability in many cancers (Honore et al., 2005; Godinho et al., 2009). 
Disturbance of the correct interaction between eRF3 and CCT subunits may affect microtubules 
stability and consequently perturb the correct chromosome segregation leading to genome 
aberrations.  
The mRNA levels of the genes encoding the CCT2 and CCT4 subunits of the CCT complex were 
reported to be up-regulated in hepatocelular carcinomas and in 83% of the colonic tumors 
(Yokota et al., 2001). Our own results also revealed that eRF3a/GSPT1 is overexpressed in 70% 
of the intestinal type gastric tumors (Malta-Vacas et al., 2005). Interestingly both eRF3a/GSPT1 
(Hoshino et al., 1998; Chauvin et al., 2007) and CCT subunits (Yokota et al., 1999; Nolasco et 
al., 2005) expression levels correlate with growth rates in mammalian cells, being up-regulated 
in the early S phase of the cell cycle. To investigate if the expression of eRF3a/GSPT1 and the 
genes encoding the components of the tubulin folding pathway are correlated, and collectively 
contribute to tumorigenesis, we quantified the expression of a number of genes belonging to 
both pathways (eRF1, eRF3a/GSPT1, PFDN4, CCT2, CCT4 and TBCA) in normal and tumoral 
gastric tissues. However, eRF3a/GSPT1 mRNA levels of expression did not correlate with any of 
the other genes analysed in gastric tissue samples. Although eRF3a/GSPT1 expression is likely to 
be independent from both cell translation rates and protein folding pathways, our results 
revealed up-regulated levels of expression of components of the translation termination and 
protein folding pathway in gastric cancer tissues, mostly in the intestinal type tumors (Malta-
Vacas et al., 2009b). Corroborating previous results (Malta-Vacas et al., 2005), the differences in 
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the patterns of expression of the genes studied support the hypothesis of genetic independent 
pathways in the origin of intestinal and diffuse type gastric tumors. 
The formation of micronuclei (MN) in dividing cells is the result of chromosome breakage due to 
unrepaired or mis-repaired DNA lesions, or chromosome malsegregation due to mitotic 
malfunction (Bonassi et al., 2007). Therefore, the MN frequency is since long considered a 
predictive biomarker of cancer risk (Eastmond & Tucker, 1989; Fenech et al., 1999; Fenech, 
2006; Mateuca et al., 2006). We used the frequency of MN as a measure of chromosomal 
damage and genome stability to evaluate if eRF3a proteins with different N-terminal lengths are 
equally competent in their putative role in microtubules stability. The frequency of MN in Jurkat-
(GGC)n cell lines revealed that the formation of MN is more frequent in cells with longer GGC 
expansions, which may be indicative that the encoded proteins allow malsegregation of 
chromatids/chromosomes by interfering with the accurate functioning of the mitotic spindle 
(Malta-Vacas et al., submitted). It is known that in cancer cells centrosomes are often found 
amplified to greater than two per cell, resulting in an increased frequency of chromosome 
segregation errors. Destabilization of chromosomes by centrosome amplification aids acquisition 
of further malignant phenotypes, hence promoting tumor progression (Gisselsson, 2005; 
Godinho et al., 2009). In accordance, several studies have reported increased MN frequencies in 
peripheral lymphocytes from cancer patients when compared with matched control populations 
(El-Zein et al., 2006; Bonassi et al., 2007, Iarmarcovai et al., 2008; Saran et al., 2008). 
 
4.4.3. eRF3a role in proliferation and apoptosis rates 
 
The regulation of protein synthesis is known to be coupled with cell cycle progression and 
regulated in response to nutrient availability and mitogenic stimulation. There is presently a 
growing body of evidence that supports the involvement of translation in cell proliferation and 
cancer development (Clemens & Bommer, 1999; Rajasekhar & Holland, 2004). 
The first eRF3 coding gene described, named gst1 (G1 to S Transition), was identified in a 
temperature-sensitive mutant of Sacharomyces cerevisae because it was required for the G1 to 
S phase transition of the cell cycle (Kikuchi et al., 1988). The mammalian eRF3a/GSPT1 gene is 
also regulated in a cell cycle-dependent manner, being up-regulated in the G1-S phase transition 
of the cell cycle (Hoshino et al., 1989; Hoshino et al., 1998; Chauvin et al., 2007).  
To evaluate whether the length of the Gly expansion in N-terminal region of eRF3a have an 
effect on the protein involvement in cell cycle regulation, we analyzed the cell cycle status of 
cells expressing different alleles, encoding proteins with 7-12 Gly residues in the N-terminal of 
eRF3a. Both in the Jurkat-(GGC)n cell lines and in primary cultured lymphocytes we found any 
significant difference in the percentage of cells in S-phase and in the proliferation index (S+G2M) 
between the (GGC)n alleles. Using the Jurkat-(GGC)n cell lines, the CBPI (cytokinesis block 
proliferation index) was also calculated as a measure of the average number of cell cycles that a 
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cell population pass through. These results also showed that the variation in the GGC expansion 
length did not affect the proliferative kinetics of the cells (Malta-Vacas et al., submitted). 
It is known that some cell cycle regulators can influence both cell division and programmed cell 
death. This means that there is an inter-connection between the molecular mechanisms that 
control the decision between proliferation and cell death. A linkage of cell cycle and apoptosis 
has been recognized for c-Myc, p53, pRb, Ras, and other cancer-related proteins (Alenzi, 2004). 
It may seem contradictory at first glance, but it is known that a number of dominant oncogenes, 
such as c-Myc, induce apoptosis under certain circumstances (Hoffman & Liebermann, 2008). 
Interestingly, a proteolytically processed isoform of the eRF3a protein was reported to function 
as an IAP (inhibitor of apoptosis protein) binding protein. The processed protein harbours a 
conserved N-terminal IAP-binding motif (AKPF), which is exposed after proteolytic cleavage of a 
69-residue leader sequence (Hegde et al., 2003). As eRF3 directly interacts with IAPs such as 
cIAP1, cIAP2 and XIAP, disturbance of the correct interaction between eRF3a and IAPs can 
release these proteins and consequently repress or even block the apoptosis pathways in which 
they are involved. The polymorphic Gly stretch is not present in the processed isoform of eRF3a, 
since it is part of the 69 N-terminal residues excluded by proteolytic cleavage. However, we 
raised the hypothesis that the number of Gly residues might interfere in the cleavage process. If 
this is the case, the amount of the processed eRF3a isoform could be influenced by the length of 
the Gly expansion. As a consequence, reduced amounts of eRF3a could repress the apoptotic 
pathways or, by contrast, an excess of eRF3a isoform could sequester higher amounts of IAPs 
and potentiate apoptosis by liberating caspases from IAP inhibition.  
Moreover, eRF3a was also reported to interact with ASK1, which plays a critical role in inducing 
apoptosis signals initiated by a variety of death stimuli. eRF3a interacts with ASK1 and enhances 
ASK1-induced apoptotic activity through the activation of caspase-3 (Lee et al., 2008). As the 
site of interaction between eRF3a and the C-terminal domain of ASK1 is not identified, it is 
possible that the length of the Gly stretch might interfere with this interaction, (des)regulating 
the apoptotic pathways activated downstream. 
To evaluate this possibility, we analyzed the apoptosis rates in cell lines expressing the 5 known 
alleles of eRF3a/GSPT1. Both in Jurkat-(GGC)n cell lines and in lymphocytes primary cultures, 
there were no significant differences between different alleles, in what concerns the number of 
viable cells, number of dead cells and total apoptotic cells (Malta-Vacas et al., submitted). Our 
results suggest that this range of repeat lengths (7 to 12 GGC) does not affect the cleavage of 
eRF3a protein into the N-truncated isoform and therefore does not have an impact in its activity 
as an IAP-binding protein. These results also suggest that the interaction between eRF3a and 
ASK1 is not likely to be affected by the number of glycine residues in eRF3a N-terminal domain. 
Although the length of the Gly expansion does not affect proliferation and apoptosis rates, eRF3a 
appears to be a key component in a cell cycle checkpoint that determines whether cells progress 
through S phase. Although the precise pathways in which it is involved are not still identified, it 
is clear that eRF3a/GSPT1 expression controls the transition from G1 to S phase. Also, eRF3a 
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regulates apoptosis by interacting both with IAPs and with the ASK1. Therefore, eRF3a is 
certainly a critical protein, implicated in mechanisms that control the decision between 
proliferation and cell death. 
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5. CHAPTER V 
FINAL REMARKS 
 
 
Both gastric cancer, colorectal cancer and breast cancer, the types of tumors used as cancer 
models during this research work, are within the main types of cancer leading to overall cancer 
mortality. All of them are heterogeneous diseases, being the contributions of different oncogenic 
mutations to this heterogeneity still not entirely understood. A small percentage of all cases are 
due to highly penetrant mutations in single genes; low penetrance susceptibility genes account 
for a high proportion of tumors, and most of them are still to be identified. Therefore, the search 
for additional cancer predisposition genes is a goal towards the improvement of cancer diagnosis 
and to a better understanding of the mechanisms underlying these diseases. 
 
The use of molecular markers and gene expression profiling provides a promising approach for 
improving the predictive accuracy of current disease prognostic indices. Molecular tests for 
diagnosis, disease prognosis and selection of treatment options, particularly in cancer, are 
gaining increased acceptance by physicians and patients. 
Oncologists who are aware of the progress in hereditary cancer syndrome diagnosis and, in 
particular, of how this effort may be effectively facilitated through a comprehensive family 
history in concert with molecular genetic studies, are in the advantaged position of designing 
highly targeted screening and management programs for the members of cancer-prone families. 
This knowledge may have impact upon the progress in the earlier diagnosis of cancer and 
provide an impetus for better diagnostic methods. 
 
A better understanding of eRF3a/GSPT1 gene regulation and its relation with cellular proliferation 
may have prognostic value and potential therapeutic applications.  
eRF3a/GSPT1 gene had never been related to cancer at the beginning of this study. By the end 
of the project, we believe that we contributed to a better comprehension of the mechanisms 
involved in eRF3a oncogenecity, and simultaneously identified a new potential molecule for anti-
cancer treatment. Our work also contributed to alert the international scientific community for 
eRF3a involvement in cancer. Therefore, this work represents a starting point for new roads in 
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cancer investigation. At this moment, other international groups are interested in this theme and 
are starting new projects concerning this issue. 
The major outcomes from this research may be summarized as follows: 
 
eRF3a/GSPT1 as a susceptibility cancer marker 
Most of the studies found in literature that evaluate the role of microsatellite polymorphisms 
contribution to cancer report variations in cancer risk that are associated with specific alleles, 
which are generally present in a significant proportion of the normal population. In our study, we 
report the presence of a specific allele (12GGC) directly associated with cancer development. 
This allele has never been detected in the normal population (represented by a control 
population of individuals without oncological pathologies and without known familiar history of 
cancer). Moreover, the presence of the 12GGC allele in cancer patients was shown to be a 
germline mutation. Therefore, we purpose that the presence of the 12GGC allele, by itself, may 
provide a new useful marker for cancer susceptibility. 
Gene expression profiles are key parameters used for the molecular characterization of tumours. 
The quantification of gene expression levels in tumour samples from cancer patients might be of 
critical importance in prediction of disease progression, drug response and even in identification 
of tumour margins to be removed by surgery. eRF3a/GSPT1 gene was shown to be over-
expressed in a significant proportion of different types of cancer. Moreover, allelic expression 
imbalance was detected, being the 12GGC allele significantly up-regulated. Although the 
mechanisms that underlie eRF3a/GSPT1 over-expression still need further elucidation, the 
expression of the gene might be of potential value for prognostic evaluation and therapeutic 
decisions. Otherwise, eRF3a/GSPT1 expression may add value if included in a genetic signature 
along with other genes, improving its predictive accuracy. 
 
 
eRF3a/GSPT1 as a potential anticancer drug target 
Many of the steps involved in translation and in ribosome biogenesis are intrinsically potential 
drug targets, because they rely on enzymatic activities (e.g. mTOR as a kinase; dyskerin as 
pseudouridine synthase). Therefore, translational alterations in human tumors present good 
opportunities for therapeutic interventions. Inhibitors of the mTOR pathway, such as rapamicin 
and analogues, are attractive targets and have been tested since decades as anti-cancer drugs. 
Gene therapy vectors including “suicide genes” with highly structured 5’UTRs are also being 
explored to take advantage of the enhanced cap-dependent translation in cancer cells. eRF3a is 
a small GTPase that modulates mRNA translation at different levels, namely regulating 
termination efficiency, recycling ribosomes for successive translation cycles, and even controlling 
initiation by a retro-control mechanism not yet well understood that involves the mTOR pathway. 
It thus represents an attractive target for cancer therapy.  
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Moreover, eRF3a appears to be a key component in a cell cycle checkpoint that determines 
whether cells progress through S phase. In addition, it was shown that this protein is also 
involved in apoptosis regulation. This suggests that cell cycle-dependent eRF3a induction may be 
critical for determining whether cells undergo appropriate cell cycle progression or, alternatively, 
undergo apoptosis. 
Finally, elements that control microtubules dynamics regulation are also known to have critical 
consequences for cell fate and thus represent potential therapeutic targets in oncology. 
Although a long way is still to be walked, the pathways in which eRF3a is involved make it a 
promising target for cancer therapy. To this end, it will be of paramount importance to assess 
genetically in vivo the relative significance in cancer pathogenesis of eRF3a in the mRNA 
translation control network, apoptosis and cytoskeleton assembly, in order to evaluate it as a 
potential target for therapy. 
 
 
 
Future investigations 
 
Hopefully this work will facilitate further investigations on the mechanisms involved in 
eRF3a/GSPT1 oncogenic potential. Suggestions for future investigations regarding the role of 
eRF3a/GSPT1 in tumorigenesis are: 
 
- to perform more comparative studies between different types of cancer in order to investigate 
the presence of the 12GGC allele in other cancer types. Hematologic malignancies are of 
particular interest because they frequently present chromosomal re-arrangements; 
 
- to analyse the genotypes from first degree relatives of patients with the 12GGC over several 
generations, to confirm the dominant type of heredity; 
 
- to continue the analysis of the role of the N-terminal domain of eRF3a in cytoskeleton 
organization. Analysis of the mitotic spindle formation in cells expressing different alleles should 
elucidate about the role of the N-terminal domain of eRF3a in the accurate functioning of the 
mitotic spindle; 
 
- to investigate if the size of the polyglycine expansion affects the interaction between eRF3a and 
UPF1, compromising the protein’s role in the nonsense-mediated mRNA decay; 
 
- to investigate if the size of the polyglycine expansion affects the interaction between eRF3a and 
PABP, altering the downstream pathways involved, namely in recycling of ribosomes and the 
stability of the transcriptome;  
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- to quantify the levels of expression of eRF3a and eRF3b in cells expressing different (GGC)n 
alleles at the mRNA level and protein level; 
 
- to investigate if the levels of eRF3a/GSPT1 mRNA expression correlate with eRF3a and/or 
eRF3a processed isoform levels; 
 
- to investigate if the expression of eRF3a/GSPT1 correlates with the levels of expression of the 
translation initiation factors and other factors acting in the mTOR pathway.  
